US20040180445A1 - Methods and compositions for purification of nucleic acid from a host cell - Google Patents

Methods and compositions for purification of nucleic acid from a host cell Download PDF

Info

Publication number
US20040180445A1
US20040180445A1 US10/387,646 US38764603A US2004180445A1 US 20040180445 A1 US20040180445 A1 US 20040180445A1 US 38764603 A US38764603 A US 38764603A US 2004180445 A1 US2004180445 A1 US 2004180445A1
Authority
US
United States
Prior art keywords
nucleic acid
propanesulfonate
ammonio
dimethyl
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/387,646
Inventor
Michael Domanico
Matt Meyers
Kristian Keane
Lisa Braun
Thomas Kolzau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiagen North American Holdings Inc
Original Assignee
Eppendorf5 Prime Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eppendorf5 Prime Inc filed Critical Eppendorf5 Prime Inc
Priority to US10/387,646 priority Critical patent/US20040180445A1/en
Assigned to EPPENDORF 5 PRIME, INC. reassignment EPPENDORF 5 PRIME, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRAUN, LISA R., DOMANICO, MICHAEL J., KEANE, KRISTIAN, MEYERS, MATT, KOLZAU, THOMAS
Priority to CNA2003801101423A priority patent/CN1768265A/en
Priority to DE60327471T priority patent/DE60327471D1/en
Priority to PCT/US2003/040175 priority patent/WO2004081175A2/en
Priority to EP03816282A priority patent/EP1601966B1/en
Priority to AT03816282T priority patent/ATE430195T1/en
Priority to AU2003297244A priority patent/AU2003297244A1/en
Publication of US20040180445A1 publication Critical patent/US20040180445A1/en
Assigned to EPPENDORF AG reassignment EPPENDORF AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EPPENDORF 5 PRIME, INC.
Assigned to QIAGEN NORTH AMERICAN HOLDINGS, INC. reassignment QIAGEN NORTH AMERICAN HOLDINGS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EPPENDORF AG
Priority to US12/358,128 priority patent/US7863050B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06Lysis of microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497Preparation composition [e.g., lysing or precipitation, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125Digestion or removing interfering materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • Y10T436/255Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction

Definitions

  • the invention generally relates to methods and compositions for isolating nucleic acid from cellular sources. More specifically, the invention relates to methods and compositions for directly isolating low molecular weight nucleic acid, for example, extrachromosomal DNA, from a crude cell lysate using an efficient one step lysis composition in conjunction with a nucleic acid capture matrix.
  • one of the more commonly used time efficient methods for isolating target nucleic acid involves an alkaline lysis technique.
  • the alkaline lysis method typically incorporates a NaOH/SDS lysis solution in sequential combination with a potassium acetate solution, and centrifugation steps to preferentially release and separate the target nucleic acid from other contaminating materials.
  • a separate centrifugation or filtration step is used to produce a cleared lysate. Alcohol precipitation of the cleared lysate is necessary to precipitate the nucleic acid.
  • the alkaline lysis method is fairly rapid, it takes approximately 30 to 45 minutes, and the purity of the resultant nucleic acid is fair, i.e., useful in restriction digestions and other more basic detection type procedures, it does not provide quality extrachromosomal nucleic acid.
  • the cleared lysate as prepared by the alkaline lysis procedure can be combined with a chaotropic substance, for example guanidinium salt, urea and sodium iodide, in the presence of a DNA-binding solid phase (e.g. beads or other binding matrix) to purify the target nucleic acid.
  • a DNA-binding solid phase e.g. beads or other binding matrix
  • the nucleic acid is bound to the solid phase in a one-step reaction, washed to remove residual contaminants and the nucleic acid is then eluted in low salt buffer.
  • the present invention provides a one-step method for lysing and isolating low molecular weight nucleic acid from host cells, using a single solution and a nucleic acid capture matrix.
  • the lysis solution is pre-chilled to enhance nucleic acid purity.
  • the nucleic acid capture matrix comprises a capture matrix material having a pore size of at least 1 ⁇ m.
  • low molecular weight nucleic acid can be isolated quickly (approximately 8 to 10 minutes) and easily (few reagents required) following the methods described herein at high yield and purity.
  • the low molecular weight nucleic acid isolated following the methods and compositions of the invention has a A 260/280 ratio of from about 1.7 to 1.9, and has minimal protein contamination as determined by visual, i.e. photometric, detection methods, i.e., standard gel electrophoresis and like methods. More preferably, low molecular weight nucleic acid isolated using the methods and compositions of the invention can typically be sequenced for at least 600 bases, i.e., having a 600 quality score (q) ⁇ 20 per sample (CodonCode software, PHRED Interphace) (PHRED q ⁇ 20 score of 600).
  • q quality score
  • the lysis composition preferably comprises a buffering agent and a detergent.
  • the detergent comprises a non-ionic detergent or a zwitterionic detergent, for example, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate.
  • the lysis composition further comprises a salt, polyethylene glycol, lysozyme, and/or RNase.
  • the lysis solution is pre-chilled prior to its addition to host cells.
  • a kit for purifying low molecular weight nucleic acid from host cells.
  • the kit includes a nucleic acid capture matrix and a lysis composition comprising a buffering agent, a non-ionic or zwitterionic detergent, and optionally a salt, polyethylene glycol, lysozyme and/or RNase.
  • the nucleic acid capture matrix comprises a capture matrix material incorporated into a spin column having an average pore size of at least about 1 ⁇ m, and more preferably at least about 3 ⁇ m.
  • Another embodiment of the present invention is a method for purifying low molecular weight nucleic acid from host cells.
  • the method includes the steps of adding a lysis composition to the host cells, wherein the lysis composition comprises from 0.2% to 6% zwitterionic or non-ionic detergent and is preferably pre-chilled prior to use, combining the released low molecular weight nucleic acid with a nucleic acid capture matrix, and eluting the captured low molecular weight nucleic acid into a capture tube.
  • the lysis composition is incubated on the host cells at room temperature for at least 2 minutes, and more preferably at least 3 minutes prior to the addition to the nucleic acid capture matrix.
  • compositions of the present invention can also be modified, as described in greater detail below, for the preferential isolation of solubilized protein, RNA, BACs, and high molecular weight nucleic acid.
  • a lysis solution comprising a buffer and zwitterionic detergent are employed in conjunction with the appropriate ingredient for high yield and quality purification of the target macromolecule, for example RNase, lysozyme, or DNase.
  • FIGS. 1A and 1B illustrate isolated plasmid DNA as visualized on a stained 0.5% agarose gel ( 1 A) and graphically ( 1 B) where the cells were incubated with Lysis solution for various amounts of time at room temperature.
  • the graph illustrates both concentration and A 212 absorbance readings for each condition.
  • FIG. 2 illustrates plasmid DNA as visualized on a stained 0.5% agarose gel where the type of detergent used in the Lysis buffer has a dramatic effect on both the yield and quality of the purified plasmid DNA.
  • the DNA was isolated on a glass fiber (second 1-12) plate.
  • FIG. 3 illustrates plasmid DNA as visualized on a stained 0.5% agarose gel where the cells were incubated with room temperature Lysis solution, 4° C. Lysis solution, or 0° C. Lysis solution.
  • FIG. 4 illustrates that the type of NA capture matrix material and the pore size of that matrix have an effect on both yield and quality of the purified plasmid DNA. Isolated plasmid DNA was visualized on a stained 0.5% agarose gel.
  • FIG. 5 illustrates that the methods and Lysis lysis solution of the present invention is useful in isolating different plasmid vectors from different types of host cells. Plasmid DNA samples were visualized on a stained 0.5% agarose gel.
  • FIG. 6 illustrates that the plasmid DNA isolated via the methods and Lysis lysis solution of the present invention provide adequate template DNA for PCR. PCR products were visualized on a stained agarose gel.
  • FIGS. 7A and 7B illustrate that the Lysis lysis method provides excellent concentrations and yields, comparable or better, to the QIAgen, Invitrogen, BioRad or Promega kits via a spectrophotometric analysis.
  • FIG. 7A shows lysis method DNA (labeled on the gel as FastPlasmid DNA) compared to QIAgen prepared DNA.
  • FIG. 7B graphically compares concentration from lysis method prepared DNA of the present invention to DNA prepared via QIAgen, Invitrogen, BioRad and Promega.
  • FIG. 8 illustrates the sequencing quality, via a sequencing trace, of DNA isolated using the methods and Lysis solutions of the present invention.
  • FIG. 9 illustrates the quality of DNA isolated using the methods and Lysis solutions of the present invention via a restriction endonuclease reaction as compared to other commonly used DNA isolation kits.
  • FIGS. 10A and B illustrate that a solution of PEG, salt and buffer can drive nucleic acid binding to silica particles.
  • a and B the isolated plasmid DNA is visualized via a 0.5% agarose gel.
  • FIG. 11 illustrates that the Lysis solution can be added directly to a liquid bacterial culture and high quality plasmid DNA isolated using the methods and materials of the present invention. Isolated DNA samples were visualized on a stained agarose gel.
  • a 260/280 refers to a commonly used nucleic acid quantitation technique where the sample to be tested is measured for absorption at approximately 260 nm and 280 nm. The ratio of absorbance at 260 to 280 is used as an indicator of nucleic acid purity. Protein contaminants tend to lower the ratio below about a ratio of 1.6 and RNA contaminants tend to raise the ratio to above 1.9-2.0.
  • a 212 refers to a single absorbance reading used to aid in the detection of protein contamination in a nucleic acid-containing sample. For example, a sample having a high A 212 reading likely has some level of protein contamination in the sample, which when combined with the A 260/280 ratio and gel agarose analysis is indicative of the sample's quality. A reading of 10 is considered high for purposes of the present invention.
  • “Host cell” refers to cells containing a target nucleic acid molecule, for example a heterologous nucleic acid molecule such as a plasmid or other low molecular weight nucleic acid, in which case the host cell is typically suitable for replicating the nucleic acid molecule of interest.
  • suitable host cells useful in the present invention include, bacterial, yeast, insect and mammalian cells. Specific examples of such cells include, SF9 insect cells, (Summers and Smith, 1987, Texas Agriculture Experiment Station Bulletin, 1555), Chinese Hamster Ovary (CHO) cells (Puck et al., 1958, Proc Natl Acad Sci USA 60:1275-1281), E.
  • Coli DH5 ⁇ cells as well as various other bacterial cell sources, for example the E. Coli strains: DH10b cells, XL1Blue cells, XL2Blue cells, Top10 cells, HB101 cells, and DH12S cells.
  • nucleic acid refers to both a deoxyribonucleic acid and a ribonucleic acid.
  • nucleic acid sequence refers to the order or sequence of deoxyribonucleotides or ribonucleotides along a strand. They may be natural or artificial sequences, and in particular genomic DNA (gDNA), complementary DNA (cDNA), messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), hybrid sequences or synthetic or semisynthetic sequences, oligonucleotides which are modified or otherwise. These nucleic acids may be of human, animal, plant, bacterial or viral origin and the like.
  • They may be obtained by any technique known to persons skilled in the art, and in particular by the screening of libraries, by chemical synthesis or by mixed methods including the chemical or enzymatic modification of sequences obtained by the screening of libraries. They may be chemically modified, e.g. they may be pseudonucleic acids (PNA), oligonucleotides modified by various chemical bonds (for example phosphorothioate or methyl phosphonate), or alternatively oligonucleotides which are functionalized, e.g. which are coupled with one or more molecules having distinct characteristic properties.
  • PNA pseudonucleic acids
  • oligonucleotides modified by various chemical bonds for example phosphorothioate or methyl phosphonate
  • oligonucleotides which are functionalized e.g. which are coupled with one or more molecules having distinct characteristic properties.
  • deoxyribonucleic acids may be single- or double-stranded, as well as short oligonucleotides or longer sequences.
  • the nucleic acids advantageously consist of plasmids, vectors, episomes, expression cassettes and the like.
  • deoxyribonucleic acids may carry genes of therapeutic interest, sequences for regulating transcription or replication, anti-sense sequences which are modified or otherwise, regions for binding to other cellular components, and the like.
  • Low molecular weight nucleic acid refers to heterologous extrachromosomal pieces of nucleic acid, for example plasmids, having a base length of approximately 2 kb to 20 kb, and in some aspects from 2 kb to 8 kb.
  • the low molecular weight nucleic acid of the invention comprises a plasmid, where the plasmid has an origin of replication or replicator, a selectable marker and a cloning site. In some instances the low molecular weight nucleic acid is supercoiled.
  • Example plasmids useful in the invention include pUC19, pUC18, pBS2, pEGFP, pBR322, and the like.
  • low molecular weight nucleic acid is envisioned to encompass other forms of nucleic acid, for example, RNA.
  • “High quality nucleic acid” as used herein generally refers to nucleic acid associated with a sufficiently low level of contaminants such that it can be digested by appropriate restriction endonuclease enzymes and can be used directly in conventional transformation and transfection procedures, i.e., no further substantial processing of the nucleic acid is required.
  • such high quality nucleic acid has a A 260/280 ratio of from about 1.6 to 2.0 and more preferably from about 1.7 to 1.9.
  • such high quality nucleic acid can be sequenced for up to at least 400 bases using standard sequencing techniques, and more preferably for up to 600 bases, typically having a PHRED score q ⁇ 20.
  • isolated and purified for purposes of the present invention are interchangeable, and refer to a polynucleotide, for example low molecular weight nucleic acid, that has been separated from cellular debris, for example, high molecular weight DNA, RNA and protein. This would include an isolated RNA sample that would be separated from cellular debris, including DNA.
  • Nucleic acid capture matrix refers to a media or material used for capturing the low molecular weight nucleic acid of the present invention, including, e.g., capture matrix materials typically composed of silica, nylon, carboxy, and the like as well as silica-based beads, including silica-coated magnetized beads.
  • the capture matrix material of the present invention comprises fiber filters having a pore size of greater than 1 ⁇ m, and more typically greater than or equal to 3 ⁇ m.
  • the nucleic acid capture matrix or “NA capture matrix” of the present invention may further comprise one or more distinct layers of capture matrix material for capture of the low molecular weight nucleic acid. It should be noted that where multiple layers of matrix material are used, the materials need not be the same in or between each layer of material.
  • the NA Capture Matrix is supported by a frit and incorporated into a conventional spin column or similar device.
  • PHRED or “PHRED score” refers to a software program used to measure DNA sequence quality.
  • the software is purchased from CodonCode Corporation, version 0.020425.c.
  • a PHRED q20 score of 600 is equivalent to approximately 730 bases at >98.5% accuracy.
  • Polyethylene glycols or “PEGs” useful in the present invention are commercially available diols having a molecular weight of from 2,000 to 10,000 daltons, and more preferably about 8,000 daltons.
  • PEG having other molecular weight constraints, for example higher than 10,000 daltons, is also contemplated for use in the compositions and methods of the present invention, although perhaps not as effective at providing a high yield/quality product.
  • detergent refers to any amphiphilic molecule having the property of being inserted into biological membranes and destabilizing them. This results from the capacity of detergent molecules to rupture the membranes by becoming inserted into the phospholipid double layers and by solubilizing the lipids and the proteins (La Cellule, Ed. Vigot and Decarie, 1988, pp. 581-583).
  • Zwitterionic detergent refers to detergents exhibiting zwitterionic character, including for example sulfobetaines sold under the brand names ZwittergentTM and AnzergentTM. Particularly suitable detergents are the following: N-dodecyl-N,N-dimethylammonio-3-propane sulfate or the corresponding N-tetradecyl or N-hexadecyl compound (type “Zwittergent”: Zwittergent 3-14, 3-16), N-dodecyl-N,N-dimethyl-glycine (Empigen BB.RTM.), aminoxide, CHAPS, CHAPSO and .alpha.-lecithin (.alpha.-phosphatidylcholin) or .alpha.-lysolecithin (.alpha.-lysophosphatidylcholin).
  • the invention provides methods and compositions for lysing and solubilizing host cells.
  • the invention provides a simple three to five minute procedure that utilizes a single solution for lysing and releasing the contents of a cell and contemporaneously solubilizing the majority of the cell's protein.
  • Embodiments of the present invention include methods and solutions for the preferential isolation of low molecular weight nucleic acid, e.g., extrachromosomal DNA, RNA, or other regions of DNA from the host cell, as well as the preferential separation of protein from nucleic acid from a host cell.
  • methods and compositions are provided for purifying low molecular weight nucleic acid, for example plasmid DNA, from target host cells.
  • plasmid DNA is purified from host bacterial cells at high yields and at a quality useful in cloning procedures, restriction digest reactions, and in sequencing reactions.
  • the methods of the invention utilize a single solution to lyse the bacterial cells and bind nucleic acid.
  • Low molecular weight nucleic acid is released from host cells and captured on a nucleic acid capture matrix directly from the crude lysate. The matrix is washed with an appropriate wash buffer and eluted in a final end-use condition. The entire procedure can be performed in less than 10 minutes and in preferred embodiments can be performed in approximately 8 or fewer minutes.
  • the invention is based upon, among other things, a lysis solution comprising a buffering ingredient and a detergent.
  • the detergent is a zwitterionic detergent, and in particular a detergent selected from the group that includes, but is not limited to, n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and the like.
  • zwitterionic detergents are envisioned to be within the scope of the present invention, especially those zwitterionic detergents that have like properties to the enumerated zwitterionic detergents above.
  • Embodiments of this solution are capable of lysing target host cells and solubilizing a majority of the cellular protein.
  • the lysis solution of the present invention can be used in conjunction with other nucleic acid isolation methods, for example a high concentration of chaotropic salt, to drive the binding of nucleic acid to a solid support matrix.
  • Preferred buffer/detergent embodiments of the solution include lysozyme and either DNase or RNase.
  • the above-described lysis solution may further comprise a chelating agent, a salt, polyethylene glycol, lysozyme, and RNase or DNase.
  • a chelating agent for removal of RNA in a DNA purification procedure, or DNase, for removal of DNA in a RNA purification procedure
  • the RNase for removal of RNA in a DNA purification procedure
  • DNase for removal of DNA in a RNA purification procedure
  • the inclusion of lysozyme has a significant impact on resultant yields, and is particularly preferred as an additional ingredient of the lysis solution of the present invention. Inclusion of these components are contemplated for use in nucleic isolation methods in accordance with the present invention.
  • the buffer component of the lysis solution is Tris-Cl having a pH of approximately 8, although other buffering compounds are contemplated.
  • the final concentration of Tris-Cl in the lysis solution is from about 0 to about 200 mM, and preferably from about 15 to 75 mM.
  • the buffering component of the solution can be modified so that little or no pH modification of the final solution is required.
  • the buffer component can be a combination of Tris-amino and Tris-amino hydrochloride to provide a final lysis solution pH of approximately 7.9 to 8.4.
  • One illustrative combination is to include approximately 17 mM Tris amino with 28 mM Tris amino hydrochloride in the final lysis solution.
  • Other buffering combinations can be used to obtain the appropriate lysis solution pH, which as mentioned above, is optimally from 7.9 to 8.4.
  • the preferred salt for use in the lysis solution is any common salt used in nucleic acid precipitation, for example, NaCl, NH 4 C 1 , NH 4 SO 4 , MgCl 2 , and the like.
  • the salt is NaCl, due partly to its availability and relative low cost.
  • Final concentrations of salt in the lysis solution preferably range from 200 to 800 mM and more preferably about 400 mM.
  • the preferred chelating agent for use in the lysis solution is EDTA, but it is contemplated that EGTA can also be used. Final concentrations of EDTA of from 0 to 20 mM, and preferably about 9 mM, are useful in embodiments of the present invention.
  • the preferred molecular weight of polyethylene glycol (PEG) for use in the present invention is about 2,000 to 10,000 daltons, and more preferably about 8,000 daltons.
  • final PEG concentration in the lysis solution is from 2 to 20% and preferably from 2 to 8%.
  • PEG is prepared by using techniques well known in the art, for example by heating to an appropriate temperature and filtering to remove particulates. Surprisingly, PEG having higher molecular weight may have deleterious effects on the quality of the purified low molecular weight nucleic acid of the present invention.
  • embodiments of the lysis solution include lysozyme, for example egg white lysozyme or recombinant lysozyme, at a final concentration of from approximately 300 to 2,000 ⁇ g/ml, and preferably from 800 to 1,200 ⁇ g/ml.
  • RNase or DNase where the purification target is RNA
  • RNase A, RNase 1, RNase T1 is preferably included in the Lysis solution at a concentration of from 200 to 400 ⁇ g/ml.
  • the lysozyme or RNase is stored as a lyophilized powder or in solution.
  • RNase is typically stored in a 100 mM NaCl, 10 mM Tris, and 1 mM EDTA solution.
  • the lysozyme and RNase are required for optimized yield, i.e., full release of the nucleic acid, and removal of RNA contaminants, respectively, and can be included at higher concentrations than disclosed above, but with limited enhancement in yield and quality. Lysozyme, RNase and DNase are commercially available.
  • the lysis solution also includes a detergent at a final concentration of from about 0.2% to 6%, and preferably from about 2 to 4%. Note that lower amounts of detergent can be used in the solutions of the present invention, especially where the concentration of cells being lysed and solubilized is low. Further, although higher levels of detergent are contemplated for use in the present invention, they may not add additional functional value and thus are less preferred.
  • the detergent is either an ionic detergent, non-ionic detergent, or a zwitterionic detergent.
  • Typical ionic detergents for use in the present invention include, but are not limited to Deoxycholic Acid.
  • Typical non-ionic detergents for use in the present invention include, but are not limited to, Triton X-100, Apo 10, Apo 12 and NP40.
  • Typical zwitterionic detergents include, but are not limited to, CHAPS and sulfobetaines, the sulfobetaine detergents sold under the brand name ZwittergentTM and AnzergentTM, for example. Note also that in some cases a non-detergent zwitterionic material can also be used, but is not preferred.
  • the detergent is a Zwitterionic detergent, for example, sold under the brand names ZwittergentTM and AnzergentTM, having the chemical names of: n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate.
  • ZwittergentTM and AnzergentTM having the chemical names of: n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-
  • detergents of the present invention can be purchased under the brand names, for example, of: Anzergent 3-14, Analytical Grade; Anzergent 3-8, Analytical Grade; Anzergent 3-10, Analytical Grade; Anzergent 3-12, Analytical Grade, respectively or zwittergent 3-8, zwittergent 3-10, zwittergent 3-12 and zwittergent 3-14, CHAPS, CHAPSO, Apo10 and Apo12.
  • compatible detergents for use in the present invention can be mixed together to provide the requisite detergent composition (final concentration) for use in the lysis solution.
  • a detergent having a final concentration of 2% in the lysis solution can be composed of a 50:50 mixture of n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate:n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate.
  • a chaotropic salt at concentrations of between 50 mM and 6M, and preferably between 200 mM and ⁇ 400 mM, can be included in the solution to assist in the denaturation of proteins.
  • an alcohol like isopropanol, may be included in the solution at concentrations of between 0.5% to 25%, to assist in the precipitation of the low molecular weight nucleic acid.
  • the lysozyme, RNase (or DNase), and detergent should be added after the other components of the solution have been brought to a pH of from 7.9 and 8.4, and preferably to a pH of about 8.1.
  • any number of well known acids or bases in the art for example, HCl or NaOH, can be used.
  • the pH of the lysis solution should be fairly close to the acceptable range by preparing the solution with the appropriate amounts and compositions of buffering solutions.
  • the lysis solution is preferably stored at 4° C., although it is envisioned that storage can also be at room temperature. Typically, solutions can be stored for up to 3 months. However, it is also envisioned that the lysis solution in the absence of RNase, DNase, and lysozyme can be stored for up to one to two years. The lysozyme, RNase and DNase may be advantageously added at the time of use from a concentrated solution or as noted above from a lyophilized powder when longer storage times are required.
  • the lysis solution is added to target host cells at a temperature of from about 0° C. to 10° C., more preferably 1° C. to 8° C., most preferably 0° C. to 4° C., generally in the range of about 2° C. to 6° C.
  • pre-chilled refers to the lysis composition of the present invention within the foregoing temperature ranges. As such, when a lysis procedure is anticipated, the lysis solution should be placed on ice for a sufficient period of time prior to use with the host cells to achieve the requisite temperature.
  • Table 1 provides an illustrative lysis solution for use in the methods of the present invention.
  • TABLE 1 Illustrative Lysis Solution Ingredient Preferred Ingr. Final Conc. Units Buffer Tris-Cl (pH 8) 45 mM Chelating agent EDTA 9 mM Salt NaCl 400 mM PEG MW 8000 8 % RNase RNase A 305 ⁇ g/ml Lysozyme Egg White Lysozyme 1000 ⁇ g/ml Detergent n-Decyl-N,N- 3 % dimethyl-3-ammonio- 1-propanesulfonate
  • the methods of the present invention are used to lyse and solubilize target host cells using embodiments of the above-described lysis solution.
  • the lysis solution comprises a buffering agent and a detergent, preferably a zwitterionic detergent.
  • the lysis solution further comprises lysozyme.
  • the lysis solution can also include other optional constituents as described above, dependent on the anticipated use of the lysed and solubilized material. For example, where isolation of RNA is anticipated, inclusion of DNase is advantageous, or where isolation of a DNA plasmid vector is anticipated, the lysis solution may include RNase.
  • the method comprises vortexing or mixing the cells with a pre-chilled lysis solution for a period of from 10 to 30 seconds, followed by a one to ten minute, and more preferably three to five minute, room temperature incubation.
  • This preferred method of the invention provides a compatible procedure to an alkaline lysis procedure, taking less than half the time and generally providing a higher quality product, i.e., cleared lysate.
  • the methods of the present invention further include performing a one-solution purification procedure on host cells that harbor target low molecular weight nucleic acid molecules.
  • the procedure results in the isolation of the low-molecular weight nucleic acid, for example plasmid DNA, directly from the lysed cells, i.e., directly from the crude cell lysate.
  • the low molecular weight nucleic acid is released from the host cells, and a substantial majority of the host cellular protein is solubilized by the composition embodiments of the present invention.
  • the released low-molecular weight nucleic acid is captured from the crude cell lysate by a nucleic acid capture matrix, and washed on that matrix in an alcohol-based buffer.
  • the resultant captured low molecular weight nucleic acid is eluted from the capture matrix in an appropriate buffer, typically at a high yield and excellent quality.
  • an appropriate buffer typically at a high yield and excellent quality.
  • a single buffer is utilized to lyse the host cell and bind/capture the target low-molecular weight nucleic acid on a solid support, i.e., the nucleic acid capture matrix.
  • the entire process as more fully described below, can be performed in approximately eight to ten minutes, and requires only standard laboratory equipment.
  • bacterial or other appropriate host cells are transformed with target low molecular weight nucleic acid, as is well known in the art.
  • the host cells are grown to a target concentration (typically 5 ⁇ 10 8 to 20 ⁇ 10 8 cells/ml or A 600 of between 1 and 4 OD units), harvested, and spun down, as is also well known in the art.
  • the LB growth media (or any other solution on the cells) is decanted off of the cell pellet, and pre-chilled lysis solution (0° C. to 4° C.) of the present invention added to the cell pellet.
  • lysis solution typically is added directed to the cell culture, i.e., prior to the cells being spun down and growth media decanted off of the cell pellet.
  • a ratio of about 2:1 to about 1:3 cells:lysis solution is combined, the ratio dependent on the cell concentration, embodiment of the lysis solution and other like parameters.
  • the lysis solution is continuously vortexed or mixed on the host cells for approximately 10 to 30 seconds, and more preferably for about 20 seconds.
  • the re-suspended cell mixture is next incubated at room temperature for a period of from one to ten minutes, and more preferably from three to five minutes, and most preferably about five minutes.
  • the room temperature incubation results in the substantial release of the low-molecular weight nucleic acid from the host cells and the solubilization of a substantial portion of the host cellular protein.
  • shorter lysis solution room temperature incubations can be used in conjunction with the present invention, although the yield of low molecular weight nucleic acid is correspondingly lower.
  • longer room temperature lysis incubations may be used, but little improvement in low molecular weight nucleic acid yield or quality is typically observed beyond the five to ten minute incubation.
  • lysis buffer temperature and host cell incubation temperature can be modified in relation to the methods of the present invention, with some effect on the overall yields and purity of low molecular weight nucleic acid.
  • the released low molecular weight nucleic acid and solubilized cellular debris is transferred to a spin column having at least one layer of nucleic acid (NA) capture matrix (preferred embodiments can have a second and/or third layer of NA capture matrix incorporated into the spin column).
  • NA nucleic acid
  • the above mixture is spun through the spin device at approximately 14,000 RPM (20,000 ⁇ G) for approximately 30 seconds using a mini- or micro-centrifuge (one of skill in the art will recognize that other speeds and times can be used in the context of the present invention as long as the fluid is pulled through the spin column, as is well known in the art). Note that other procedures can be used in this aspect as well, for example vacuum filtering and the like of the material through the nucleic acid capture matrix.
  • NA capture matrix material is included directly in the lysis buffer and added directly to the host cells during the room temperature lysis buffer/host cell incubation.
  • the lysis buffer/nucleic acid capture matrix must be thoroughly mixed before addition to the host cell pellet so that the matrix is thoroughly re-suspended.
  • the NA capture matrix binds a portion of the released low molecular weight nucleic acid from the cellular debris, i.e., crude lysate.
  • nucleic acid capture matrix with a pore size of greater than 1-2 ⁇ m is preferred for use in the invention, and preferably, multiple layers of nucleic acid capture matrix, each having pore sizes of at least 1-2 ⁇ m is used during capture of the low molecular weight nucleic acid.
  • matrix materials having pore sizes of less than 1-2 ⁇ m are also envisioned for use in the present invention, but display a tendency to become clogged and require additional processing not necessary with the larger pore materials.
  • the larger pore materials preferred for use herein tend to provide superior capture characteristics in conjunction with the invention not present in smaller pore materials
  • wash buffer is typically a 20 mM Tris-Cl, pH of 7.2, 0.2 M NaCl, and 2 mM EDTA, pH of 8.0)/isopropanol solution.
  • the ratio of Tris buffer:Isopropanol is about 30-35:70-65, and is preferably about 32.5:67.5 (note that other like alcohols can be used in place of isopropanol, for example ethanol).
  • wash buffer compositions can be used with the present invention as long as they preferentially dissociate contaminants to low molecular weight nucleic acid from the capture matrix.
  • the wash step removes loosely associated protein and other macromolecules from the loaded nucleic acid capture matrix.
  • the low-molecular weight nucleic acid is eluted from the NA capture matrix using a 10 mM Tris, 0.1 mM EDTA solution, having a pH of approximately 8.5.
  • Typical elution parameters include using smaller volumes to maintain a higher concentration of the target low molecular weigh nucleic acid, and minimizing the amount of EDTA or other enzyme inhibitory constituents in the elution buffer.
  • elution of the low molecular weight nucleic acid can be performed in a solution compatible with the end-use application, for example, using an elution buffer having little inhibitory activity on polymerase enzymes.
  • the end-use application can be performed directly on the eluted sample without having to precipitate and re-suspend the nucleic acid in the appropriate buffer.
  • Other elution buffer solutions for use in the present invention include water, TE buffer, 10-50 mM Tris buffer, and the like.
  • Capture matrix compositions for use in the present invention include silica-, nylon-, and acrylic-based materials. Typical pore sizes for the filter capture matrix material are from 1 to 25 ⁇ m, and preferably from 1 to 5 ⁇ m, and most preferably from 3 to 5 ⁇ m. It is noted that matrix materials having larger pore sizes can be used in conjunction with the present invention, but are likely less effective in capturing low molecular weight nucleic acid.
  • smaller pore size capture matrix materials i.e., smaller than 1 ⁇ m
  • matrix materials having pore sizes of between 1 and 2 ⁇ m can also show some level of clogging, dependent on the number of matrix layers and size of sample).
  • a first layer of capture matrix material is incorporated into a spin device as is well known in the art.
  • the capture matrix material will be of a composition and pore size compatible with the parameters previously described, but is preferably a glass fiber having a pore size of between 3 to 5 ⁇ m.
  • the spin device includes two layers of capture matrix material, for example, a first (top) layer of material having a pore size of approximately 5 ⁇ m and a second layer (lower) of capture matrix material having a pore size of approximately 3 ⁇ m.
  • the additional capture matrix material provides an additional surface area/support for the capture of the target low-molecular weight nucleic acid.
  • the two layers are of different materials, although it is envisioned that the two layers can be the same material.
  • pore size between layers is typically different, with the larger pore size material on top of the smaller pore size material.
  • additional capture matrix material layers may be added, although clogging of the filter material may become a greater concern.
  • a frit may be included in the NA capture matrix, below the one or more capture matrix material layers for support.
  • a typical frit is composed of an inert material, for example polyethylene, having a pore size of between 5 to 70 ⁇ m.
  • a portion, for example 350 ⁇ l of NA capture matrix slurry e.g., a silica bead in solution
  • NA capture matrix slurry e.g., a silica bead in solution
  • the capture matrix slurry/lysis solution mixture is spun down as above, and the pelleted matrix washed with an appropriate wash buffer.
  • the captured low molecular weight nucleic acid is released in an appropriate elution buffer.
  • silica coated magnetized beads can be utilized as the NA capture matrix. The use and preparation of these beads is described in U.S. Pat. No. 6,368,800, which is incorporated herein by reference. Use of the silica coated magnetized beads obviates the need for centrifugation steps during the purification of target nucleic acid.
  • Table 2 provides illustrative NA capture matrix materials with corresponding pore sizes as well as several commercially available spin devices.
  • NA Capture Matrix Materials NA Capture Matrix Source Glass Fiber Ahlstrom 141, 142 Whatman GF/C, GF/D Nylon Pall Biodyne
  • compositions of the present invention are useful in the isolation of high-yield and high-quality low molecular weight nucleic acid from target host cells during high throughput applications.
  • the methods of the present invention can be performed on one sample at a time using standard laboratory equipment and personnel. However, due to the limited number of steps/compositions required to perform the methods of the present invention, and due to the limited level of complexity of those steps, it is envisioned that the methods be utilized in a highly automated procedure for isolating target nucleic acid samples from a plurality of discretely handled samples.
  • compositions and methods of the present invention can be used in a multi-well, for example 96 or 384 well, protocol.
  • Cells are grown in the appropriate number of wells required for the particular procedure. After appropriate cell growth, the cells are pelleted using a multi-well plate centrifuge. Each cell sample in the multi-well plate is re-suspended in approximately 400 ⁇ l of pre-chilled lysis solution. Plates are shaken, or each wells constituents pipetted using a multi-channel pipette or 96-pin head, in order to re-suspend the cells completely. Samples are incubated for approximately 3 to 5 minutes at room temperature.
  • the lysate from each well is transferred to a corresponding multi-well filter plate.
  • the lysate is vacuumed through the filter matrix (same types of capture matrix formats as discussed above) to capture the low-molecular weight nucleic acid on the capture matrix.
  • approximately 400 ⁇ l of wash buffer is added to each well of the filter plate. Wash buffer is pulled over the capture matrix to remove residual protein and nucleic acid, and the vacuum is pulled until much of the residual alcohol is removed from the captured low-molecular weight nucleic acid.
  • Appropriate plates are prepared for receiving the eluted low-molecular weight nucleic acid, and elution performed on each sample. This process of forcing liquids through the filter plate can also be performed using centrifugation. Note that centrifugation should be avoided during the automation process where the process is being performed on a automation workstation.
  • This process can be automated into a high-throughput procedure using pre-calibrated equipment.
  • Other methods are envisioned for high-throughput operations and are not limited to 96-well or 384-well plates.
  • the methods of the present invention are ideal for the automated preparation of a large number of discrete high quality low molecular weight nucleic acid samples.
  • kits for the performance of the above described nucleic acid purification/isolation methods include a lysis solution and NA capture matrix material (either as a spin column or matrix slurry).
  • a preferred embodiment the kit further includes an elution solution and wash buffer.
  • the kits of the present invention can also include molecular biology grade water, collection tubes, 384 well plates (optionally incorporating NA capture matrix), 96 well plates (optionally incorporating NA capture matrix), pipette tips, microcentrifuge, protective gloves, etc.
  • kits can contain lyophilized lysozyme, RNase and/or DNase that can be added to the lysis solution at the time of the kits first use.
  • the detergent can also be provided separately for addition to the other ingredients just prior to use.
  • kits it is envisioned that a plurality of tubes used in the culture of cells, for example the Lid-Bac tube (U.S. Pat. Nos. 5,958,778 and 6,503,455, incorporated herein by reference), can also be included. These tubes would allow for the culture of target cells and the processing, lysis and solubilization of those same cells to be accomplished all in a single tube, using the lysis solution and methods of the present invention.
  • the target nucleic acid is then isolated in that same tube by addition of a nucleic acid capture matrix slurry or in a second tube, for example a spin device having a layer of nucleic acid capture matrix directly incorporated therein.
  • a solution that includes a buffer, PEG, and salt is used to preferentially bind nucleic acid from a cleared lysate to a silica fiber.
  • a preferred binding solution includes from 1 to 20% PEG having a molecular weight of from 2,000 to 10,000 daltons; from about 100 to 2000 mM salt, for example NaCl; from about 10 to 200 mM buffer, for example, Tris.
  • NA capture matrix for use with this binding buffer includes silica beads and fibers.
  • Preferred silica fibers have pores of from 1 to 20 ⁇ m, and more preferably from 3 to 5 ⁇ m.
  • Table 3 provides the composition of one potential lysis solution of the present invention. The concentration of each constituent is addressed for the amount of weight per liter of solution.
  • Example 1095 The following Example illustrates that a three to ten minute room temperature incubation, and preferably a five minute room temperature incubation, of the lysis buffer on plasmid containing bacterial cells is beneficial for high yield recovery of high quality plasmid DNA.
  • Bacterial host cells were transformed with pUC19 plasmid and grown in 96 well plates overnight as is well known in the art. Plates were thawed for 15 minutes at room temperature, and approximately 400 ⁇ l of previously described Lysis buffer added per well of each plate. Note that the Lysis buffer was pre-chilled to 0° C. before addition to the bacterial cultures.
  • FIG. 1A isolated plasmid DNA from each incubation condition was run on a 0.5% agarose gel.
  • the ethidium bromide stained gel shows that all incubation conditions provided a good yield of plasmid DNA, including the immediate spin condition.
  • FIG. 1B and Table 4 provide a graphical and tabular illustration of each sample's concentration and A 212 value in relation to the incubation time. Note that as room temperature incubation period proceed, the protein contamination in the sample decreased until about three minutes, at which time the protein and nucleic acid concentrations in the sample stabilize. Taken together, FIGS.
  • FIG. 1A and 1B illustrate that a room temperature incubation of Lysis buffer on the target cells decreases the protein contamination of the isolated pUC19 while not adversely affecting the yield of the plasmid.
  • This Example shows that a three to ten minute, and preferably a five minute, room temperature incubation of the Lysis on the host cells is useful for maximizing resultant low-molecular weight nucleic acid yield and purity.
  • shorter incubations zero to two minutes, appear to not fully allow for the contaminants to be separated from the target nucleic acid using the solutions and methods of the present invention. Note that the high concentration of DNA of short incubation times, as determined by absorbance readings, are inflated due to contamination and do not represent the actual concentrations.
  • a series of 12 different lysis buffers was prepared using this base composition above, each having a different type of detergent added to a final concentration of 1%.
  • the detergents were (1) N,N′,N′-Polyoxyethylene(10)-N-tallow-1,3-diaminopropaned (N,N,N-PTD), (2) NDSB-195, (3) NDSB-201, (4) NDSB-256, (5) Apo-10, (6) Apo-12, (7) CHAPS, (8) n-Octyl-B-D-glucopyranoside, (9) De-Oxcholic Acid, (10) SDS, (11) Triton X-100 mixed with SDS (50:50), and (12) Triton X-100.
  • the lysis buffer can be brought to a pH of 8.5 in the absence of the RNase, lysozyme and detergent.
  • the type of detergent used in the lysis buffer had a dramatic effect on both the yield and quality of the purified plasmid DNA.
  • the inclusion of N,N,N-PTD detergent resulted in a high yield/high quality one-step plasmid preparation, whereas under the exact same conditions, the inclusion of De-oxcholic Acid provided adequate yield of plasmid DNA, but lower quality purified plasmid DNA.
  • detergent type had a profound effect on resultant yield and quality.
  • zwitterionic detergents were used at concentrations of between 1 to 4% to determine whether all or specific types of zwitterionic detergents are effective in the methods of the present invention.
  • n-ocytl-N,N-dimethyl-3-ammonio-1-propanesulfonate (zw-8), n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (zw-10), n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (zw-12) and n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (zw-14) all showed either adequate (zw-8) or good results (zw-10, zw-12 and zw-14) (data not shown).
  • Lysis solution as described in the Examples above was prepared having either a detergent composed of 3% zw 3-10, 3% zw 3-12, or 3% zw 3-14. Lysis solutions for each detergent condition were either left at room temperature, chilled to 4° C. or chilled to about 0° C. before addition to the cells. Results in Table 6 and FIG. 3 illustrate that the DNA isolated using the chilled lysis solutions (4° C. and 0° C.) provided higher quality isolated DNA than the DNA isolated using the lysis solution at room temperature. Lanes 3-18 in FIG.
  • the lysis methods of the present invention were used to evaluate a number of filter membrane substances, having different compositions and pore sizes, for effectiveness in isolating high quality low molecular weight nucleic acid. Both filter type and pore size were investigated for effectiveness at isolating high yield and high quality low-molecular weight nucleic acid.
  • target low molecular weight nucleic acid was propagated in target host cells in 96-well culture plates. Host cells were grown to a predetermined concentration, and cells spun down and growth media removed. Approximately 240 ⁇ l of pre-chilled lysis solution was added to each well and the cells re-suspended on a plate shaker for two minutes at a seven setting.
  • Filter conditions were varied in wells of filter plates, where wells in each plate had one of six filter combinations, which were prepared as follows: Sample 1 included a two layer NA capture matrix: layer one (top) was a glass fiber layer (1.2 ⁇ m pore size), layer two (middle) was a glass fiber (0.8 ⁇ m) and the frit was polyethylene; sample 2 included the same combination as sample one except the frit was hydrophobic; sample 3 included two layers, a first layer of 23 ⁇ m glass fiber filter on top of a frit having a pore size of 25 ⁇ m; sample 4 included a 11 ⁇ m glass fiber filter/polypropylene 25-30 ⁇ m combination; sample 5 included a 20 ⁇ m/11 ⁇ m glass fiber filters on a polypropylene 25-30 ⁇ m combination and sample 6 included a 7 ⁇ m glass fiber filter on a polypropylene 25-30 ⁇ m combination.
  • treated samples were contacted to either a nylon, PVDF or glass fiber filter having pore sizes as described: (1) 0.45 ⁇ m Nylon fiber, (2) 1.2 ⁇ m Nylon fiber, (3) 5.0 ⁇ m Nylon fiber, (4) Pallflex® Emfab filter with 70 ⁇ m frit, (5) 0.45 ⁇ m PVDF, (6) 1.0 ⁇ m Glass fiber filter, (7) two layers of 1.2 ⁇ m glass fiber filters, (8) 23 ⁇ m glass fiber filter. (9) 5 ⁇ m glass fiber filter over a 3 ⁇ m glass fiber filter over a 20 ⁇ m frit.
  • FIG. 4 indicates that although isolation of the plasmid DNA using either nylon or Pallflex yielded adequate results, the glass fiber material, and in particular the two layers of glass fiber material in sample 9 provided for an excellent NA capture matrix in the context of the present invention.
  • the quality of the isolated plasmid DNA showed good A 260 /A 280 ratios and A 212 readings, especially with regard to sample 9—the two layer glass fiber capture matrix having a first layer with a pore size of 5 ⁇ m and the second layer having a pore size of 3 ⁇ m.
  • Example 2 The data in the following Example illustrates that the lysis solutions are useful for the isolation of different sized plasmid DNA from several different host cells. Host cell/vector combinations were grown in LB/amp media overnight for 14 to 16 hours. Each cell condition consisted of 1.5 ml of pelleted culture, which was processed with 400 ⁇ l lysis solution (see Example 1). Data shown in Table 11 and FIG. 5, illustrate that the present methods and compositions are useful with a number of different host cells and different plasmids.
  • Purified low molecular weight nucleic acid may be directly amplified in a PCR reaction after recovery from the host cell using the methods and compositions of the present invention.
  • Bacterial cells having a pGEM clone from a mouse cDNA library were treated using the methods and solutions of the present invention, and isolated pGEM was used directly in a PCR reaction, i.e., no additional steps performed on the pGEM after its elution off of the NA capture matrix of the present invention.
  • the PCR reaction incorporated a T7 and a Sp6 primer and was performed using PCR methods well known in the art.
  • the pGEM DNA isolated using the methods and compositions of the present invention was an excellent template for PCR. This data indicates that the present invention provides quality DNA that can be directly used in PCR, importantly, the DNA does not require additional manipulation for its use in these reactions.
  • Plasmid DNA can be Isolated in a 96-Well Format Using the Methods and Compositions of the Present Invention
  • Bacterial host cells having a pUC19 plasmid were grown in 96-well plates to determine whether the methods and compositions of the present invention are applicable to high throughput applications.
  • the data in this Example illustrates that the methods and compositions of the present invention are adaptable to high throughput applications, for example, 96-well format plates. Further the data indicates that mixing the cells with lysis solution can be accomplished by shaking the plates on a plate shaker, vortexing the plates on a plate vortex or pipetting the contents of each well using a 96 well pin. TABLE 12 Data From 48 Wells of a 96 Well Plate Well Number A 260 /A 280 Concen.
  • the quality of the plasmid DNA isolated using the lysis solution were compared to plasmid DNA isolated using QIAprep Miniprep kit, Wizard® Plus SV Minipreps DNA purification system (Promega), Aurum® Plasmid Mini Kit (BioRad), S.N.A.P. MiniPrep Kit (Invitrogen). Similar numbers of starting cells and elution volumes were used for each method.
  • Spectrophotometric Analysis Samples from each of the purification methods were analyzed using a SPECTRAmax Microplate Spectrophotometer (Molecular Devices Corp.) to determine DNA concentration and purity. Samples were diluted 20 fold in a UV-Star 96 well plate (Greiner bio-one Corp.). Absorbance readings were taken at the following wavelengths, 260, 280, and 212 nm. Each sample was run in duplicate. Concentration and A 260 / 280 ratios were averaged to determine values presented in FIG. 7B. The data in FIG. 7B illustrates that the instant lysis method provides excellent concentrations and yields, comparable or better, to the QIAgen, Invitrogen, BioRad or Promega kits.
  • DNA Sequencing Samples for each method were further analyzed by sequencing with ABI BigDyeTM Terminator chemistry on the ABI 3700 sequencer. Sequencing was performed on the plasmid DNA and performed in duplicate. Template DNA was added to the reaction and varied according to vector and pelleted starting material. Between 200 ng and 300 ng of template DNA was aliquoted into a 96 well plate (Genemate-ISC Bioexpress) in a total volume of 41 ⁇ l. Sequencing parameters were as follows: step 1-94° C. for two minutes; step 2-94° C. for ten seconds; step 3-50° C. for five seconds; step 4-70° C. for four minutes; step 5—go to step two and repeat 25 times and step 6-10° C. hold.
  • Sequencing cleanup was performed prior to loading onto the ABI 3700 DNA sequencer. Approximately fifteen micro liters of 99% isopropanol was added to each well and heat sealed using Expender Heat Sealer and then vortexed briefly. Samples were incubated at room temperature for fifteen minutes and centrifuged at 1900 ⁇ g for thirty minutes. Following centrifugation the heat seal was removed and the plate inverted on a paper towel and returned to the centrifuge plate carrier upside-down. The plate was spun at 500 ⁇ g for one minute. The plate was removed and the centrifuge and DNA resuspended in ten micro liters of ⁇ fraction (1/10) ⁇ TE and loaded onto the sequencer. Quality score was performed using PHRED based software version 0.020425.c (CodonCorporation). Passing results were determined to be those samples with 100 quality score ⁇ 20.
  • FIG. 8 provides an illustrative sequencing trace for each kit's DNA.
  • the data indicates that the instant lysis and purification methods and compositions provide comparable quality DNA to the DNA isolated using the other kit manufacturers. Note that the instant method, including elution steps, is performed in approximately 14 minutes, whereas QIAgen takes approximately 28 minutes, Invitrogen takes approximately 31 minutes, Promega takes approximately 36 minutes, and BioRad Aurum kit takes approximately 23 minutes. This data illustrates the improved utility of the lysis solutions and methods described herein.
  • Restriction Enzyme Digestion Restriction digestion was performed on the pSV- ⁇ -gal vector using EcoRI, Hind III and Ned I. Restriction digestions were performed on 250 ng of plasmid DNA and 1 unit of each endonuclease. Buffer conditions are as described by the enzyme manufacturer. As shown in FIG. 9, the lysis isolated DNA provided comparable template DNA for restriction endonuclease as did other conventional isolation methods.
  • Example 2 The data in the following Example illustrates that the lysis solution described herein is effective in the methods of the present invention even when added directly to a liquid bacterial culture (cells not pelleted). Lysis solution was prepared as described in Example 1. Samples were added to either a multi-layer glass fiber (5 ⁇ m and 3 ⁇ m) filter device or a single layer Whatman 23 ⁇ m glass fiber filter device.
  • Type Sample # A 260 A 280 A 260/280 ⁇ g/ml A 212 Single 23 ⁇ m glass 1 0.03/0.03 0.02/0.02 1.72/1.75 33/32.7 2.5/2.4 fiber filter 2 0.03/0.04 0.02/0.02 1.77/1.7 33/34.9 2.6/2.6 3 0.03/0.03 0.02/0.02 1.76/1.76 30.9/29.7 2.2/2.2 4 0.04/0.04 0.02/0.02 1.73/1.79 37.8/37.6 3.5/3.5 Multiple: 1 0.03/0.03 0.02/0.02 1.66/1.62 33.4/31.1 2.7/2.5 5 and 3 ⁇ m glass fiber filter 2 0.03/0.03 0.02/0.02 1.74/1.74 34.3/34.3 1.9/1.9 3 0.04/0.04 0.02/0.02 1.64/1.55 37.6/37.3 1.8/1.9 4 0.04/0.04 0.02/0.02 1.58/1.56 35.5/37.8 1.8/1.8/1.8/1.8

Abstract

Methods and compositions are provided for gently lysing and solubilizing cells. Methods and compositions are further provided for quickly purifying high quality low molecular weight nucleic acid from host cells. Target cells are treated with a pre-chilled lysis solution having a zwitterionic detergent, for example n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and a brief room-temperature incubation. Where nucleic acid purification is required, the lysis solution-treated cells are contacted with a nucleic acid capture matrix having an average pore size of at least about 1 μm.

Description

    FIELD OF THE INVENTION
  • The invention generally relates to methods and compositions for isolating nucleic acid from cellular sources. More specifically, the invention relates to methods and compositions for directly isolating low molecular weight nucleic acid, for example, extrachromosomal DNA, from a crude cell lysate using an efficient one step lysis composition in conjunction with a nucleic acid capture matrix. [0001]
  • BACKGROUND OF THE INVENTION
  • The ability to isolate low molecular weight nucleic acid, and extrachromosomal nucleic acid in particular, from a host cell is often requisite to a large number of protocols used in molecular biology, as well as a basic requirement in a number of downstream uses in biotechnology and clinical research. For example, typical cloning protocols anticipate the availability of plasmid vector DNA for the transformation of target cells. The quality, i.e., level of purity and integrity, of the extrachromosomal nucleic acid is often determinative of the success of the cloning procedure, and as such, is a critical parameter for the entire procedure. Further, DNA sequencing, restriction digestion reactions and subsequent ligation reactions, are generally dependent on the quality of the starting DNA material. As such, there has been, and continues to be, a need for reliable methods for purifying high quality low molecular weight nucleic acid from host cells. [0002]
  • Conventional low molecular weight nucleic acid purification schemes often progress in more or less two stages: in the first stage, host cells harboring the target nucleic acid, i.e. extrachromosomal nucleic acid, are gently lysed and the contents solubilized; and in the second stage, the target nucleic acid is separated from the contaminating protein, RNA, high molecular weight nucleic acid (i.e. chromosomal DNA), and other macromolecules via one of several commonly used chemical or enzymatic methods. In general, conventional target nucleic acid purification schemes have proven to be either labor intensive and time consuming, yet yielding a high quality product, or relatively fast and labor efficient, but yielding a relatively low quality product. [0003]
  • More particularly, one of the more commonly used time efficient methods for isolating target nucleic acid involves an alkaline lysis technique. The alkaline lysis method typically incorporates a NaOH/SDS lysis solution in sequential combination with a potassium acetate solution, and centrifugation steps to preferentially release and separate the target nucleic acid from other contaminating materials. A separate centrifugation or filtration step is used to produce a cleared lysate. Alcohol precipitation of the cleared lysate is necessary to precipitate the nucleic acid. Although the alkaline lysis method is fairly rapid, it takes approximately 30 to 45 minutes, and the purity of the resultant nucleic acid is fair, i.e., useful in restriction digestions and other more basic detection type procedures, it does not provide quality extrachromosomal nucleic acid. [0004]
  • In a further approach, the cleared lysate as prepared by the alkaline lysis procedure can be combined with a chaotropic substance, for example guanidinium salt, urea and sodium iodide, in the presence of a DNA-binding solid phase (e.g. beads or other binding matrix) to purify the target nucleic acid. The nucleic acid is bound to the solid phase in a one-step reaction, washed to remove residual contaminants and the nucleic acid is then eluted in low salt buffer. Although methods combining alkaline lysis with the chaotropic bind/wash/elute steps can provide higher quality nucleic acid, they are still time-consuming, taking approximately twenty-five minutes, and require more handing. [0005]
  • As such, there is a continuing need in the art for a simple and time efficient method, and corresponding solutions, for purifying a low molecular weight target nucleic acid such as extrachromosomal DNA from host cells, and in particular, for methods and solutions for purifying plasmid DNA from host cells. Against this backdrop the present invention has been developed. [0006]
  • SUMMARY OF THE INVENTION
  • The present invention provides a one-step method for lysing and isolating low molecular weight nucleic acid from host cells, using a single solution and a nucleic acid capture matrix. In a preferred embodiment, the lysis solution is pre-chilled to enhance nucleic acid purity. In a further preferred embodiment, the nucleic acid capture matrix comprises a capture matrix material having a pore size of at least 1 μm. In contrast to prior art protocols, low molecular weight nucleic acid can be isolated quickly (approximately 8 to 10 minutes) and easily (few reagents required) following the methods described herein at high yield and purity. [0007]
  • Preferably, the low molecular weight nucleic acid isolated following the methods and compositions of the invention has a A[0008] 260/280 ratio of from about 1.7 to 1.9, and has minimal protein contamination as determined by visual, i.e. photometric, detection methods, i.e., standard gel electrophoresis and like methods. More preferably, low molecular weight nucleic acid isolated using the methods and compositions of the invention can typically be sequenced for at least 600 bases, i.e., having a 600 quality score (q) ≧20 per sample (CodonCode software, PHRED Interphace) (PHRED q≧20 score of 600).
  • One embodiment of the present invention provides a lysis composition for purifying low molecular weight nucleic acid from host cells. The lysis composition preferably comprises a buffering agent and a detergent. In a particularly preferred embodiment, the detergent comprises a non-ionic detergent or a zwitterionic detergent, for example, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate. In additional embodiments, the lysis composition further comprises a salt, polyethylene glycol, lysozyme, and/or RNase. [0009]
  • In a further preferred embodiment, the lysis solution is pre-chilled prior to its addition to host cells. [0010]
  • In another embodiment of the invention a kit is provided for purifying low molecular weight nucleic acid from host cells. Preferably, the kit includes a nucleic acid capture matrix and a lysis composition comprising a buffering agent, a non-ionic or zwitterionic detergent, and optionally a salt, polyethylene glycol, lysozyme and/or RNase. In a particularly preferred embodiment, the nucleic acid capture matrix comprises a capture matrix material incorporated into a spin column having an average pore size of at least about 1 μm, and more preferably at least about 3 μm. [0011]
  • Another embodiment of the present invention is a method for purifying low molecular weight nucleic acid from host cells. The method includes the steps of adding a lysis composition to the host cells, wherein the lysis composition comprises from 0.2% to 6% zwitterionic or non-ionic detergent and is preferably pre-chilled prior to use, combining the released low molecular weight nucleic acid with a nucleic acid capture matrix, and eluting the captured low molecular weight nucleic acid into a capture tube. In alternative embodiments, the lysis composition is incubated on the host cells at room temperature for at least 2 minutes, and more preferably at least 3 minutes prior to the addition to the nucleic acid capture matrix. [0012]
  • Additionally, the methods and compositions of the present invention can also be modified, as described in greater detail below, for the preferential isolation of solubilized protein, RNA, BACs, and high molecular weight nucleic acid. In these further embodiments, a lysis solution comprising a buffer and zwitterionic detergent are employed in conjunction with the appropriate ingredient for high yield and quality purification of the target macromolecule, for example RNase, lysozyme, or DNase. [0013]
  • These and various other features as well as advantages which characterize the invention will be apparent from a reading of the following detailed description and a review of the appended claims. [0014]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1A and 1B illustrate isolated plasmid DNA as visualized on a stained 0.5% agarose gel ([0015] 1A) and graphically (1B) where the cells were incubated with Lysis solution for various amounts of time at room temperature. The graph illustrates both concentration and A212 absorbance readings for each condition.
  • FIG. 2 illustrates plasmid DNA as visualized on a stained 0.5% agarose gel where the type of detergent used in the Lysis buffer has a dramatic effect on both the yield and quality of the purified plasmid DNA. The DNA was isolated on a glass fiber (second 1-12) plate. [0016]
  • FIG. 3 illustrates plasmid DNA as visualized on a stained 0.5% agarose gel where the cells were incubated with room temperature Lysis solution, 4° C. Lysis solution, or 0° C. Lysis solution. [0017]
  • FIG. 4 illustrates that the type of NA capture matrix material and the pore size of that matrix have an effect on both yield and quality of the purified plasmid DNA. Isolated plasmid DNA was visualized on a stained 0.5% agarose gel. [0018]
  • FIG. 5 illustrates that the methods and Lysis lysis solution of the present invention is useful in isolating different plasmid vectors from different types of host cells. Plasmid DNA samples were visualized on a stained 0.5% agarose gel. [0019]
  • FIG. 6 illustrates that the plasmid DNA isolated via the methods and Lysis lysis solution of the present invention provide adequate template DNA for PCR. PCR products were visualized on a stained agarose gel. [0020]
  • FIGS. 7A and 7B illustrate that the Lysis lysis method provides excellent concentrations and yields, comparable or better, to the QIAgen, Invitrogen, BioRad or Promega kits via a spectrophotometric analysis. FIG. 7A shows lysis method DNA (labeled on the gel as FastPlasmid DNA) compared to QIAgen prepared DNA. FIG. 7B graphically compares concentration from lysis method prepared DNA of the present invention to DNA prepared via QIAgen, Invitrogen, BioRad and Promega. [0021]
  • FIG. 8 illustrates the sequencing quality, via a sequencing trace, of DNA isolated using the methods and Lysis solutions of the present invention. [0022]
  • FIG. 9 illustrates the quality of DNA isolated using the methods and Lysis solutions of the present invention via a restriction endonuclease reaction as compared to other commonly used DNA isolation kits. [0023]
  • FIGS. 10A and B illustrate that a solution of PEG, salt and buffer can drive nucleic acid binding to silica particles. In A and B, the isolated plasmid DNA is visualized via a 0.5% agarose gel. [0024]
  • FIG. 11 illustrates that the Lysis solution can be added directly to a liquid bacterial culture and high quality plasmid DNA isolated using the methods and materials of the present invention. Isolated DNA samples were visualized on a stained agarose gel.[0025]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Definitions: [0026]
  • The following definitions are provided to facilitate understanding of certain terms used herein and are not meant to limit the scope of the present disclosure. [0027]
  • “A[0028] 260/280” refers to a commonly used nucleic acid quantitation technique where the sample to be tested is measured for absorption at approximately 260 nm and 280 nm. The ratio of absorbance at 260 to 280 is used as an indicator of nucleic acid purity. Protein contaminants tend to lower the ratio below about a ratio of 1.6 and RNA contaminants tend to raise the ratio to above 1.9-2.0.
  • “A[0029] 212” refers to a single absorbance reading used to aid in the detection of protein contamination in a nucleic acid-containing sample. For example, a sample having a high A212 reading likely has some level of protein contamination in the sample, which when combined with the A260/280 ratio and gel agarose analysis is indicative of the sample's quality. A reading of 10 is considered high for purposes of the present invention.
  • “Host cell” refers to cells containing a target nucleic acid molecule, for example a heterologous nucleic acid molecule such as a plasmid or other low molecular weight nucleic acid, in which case the host cell is typically suitable for replicating the nucleic acid molecule of interest. Examples of suitable host cells useful in the present invention include, bacterial, yeast, insect and mammalian cells. Specific examples of such cells include, SF9 insect cells, (Summers and Smith, 1987, Texas Agriculture Experiment Station Bulletin, 1555), Chinese Hamster Ovary (CHO) cells (Puck et al., 1958, Proc Natl Acad Sci USA 60:1275-1281), [0030] E. Coli DH5α cells, as well as various other bacterial cell sources, for example the E. Coli strains: DH10b cells, XL1Blue cells, XL2Blue cells, Top10 cells, HB101 cells, and DH12S cells.
  • As used herein, “nucleic acid” or “NA” refers to both a deoxyribonucleic acid and a ribonucleic acid. As used herein, “nucleic acid sequence” refers to the order or sequence of deoxyribonucleotides or ribonucleotides along a strand. They may be natural or artificial sequences, and in particular genomic DNA (gDNA), complementary DNA (cDNA), messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), hybrid sequences or synthetic or semisynthetic sequences, oligonucleotides which are modified or otherwise. These nucleic acids may be of human, animal, plant, bacterial or viral origin and the like. They may be obtained by any technique known to persons skilled in the art, and in particular by the screening of libraries, by chemical synthesis or by mixed methods including the chemical or enzymatic modification of sequences obtained by the screening of libraries. They may be chemically modified, e.g. they may be pseudonucleic acids (PNA), oligonucleotides modified by various chemical bonds (for example phosphorothioate or methyl phosphonate), or alternatively oligonucleotides which are functionalized, e.g. which are coupled with one or more molecules having distinct characteristic properties. [0031]
  • In the case of deoxyribonucleic acids, they may be single- or double-stranded, as well as short oligonucleotides or longer sequences. In particular, the nucleic acids advantageously consist of plasmids, vectors, episomes, expression cassettes and the like. These deoxyribonucleic acids may carry genes of therapeutic interest, sequences for regulating transcription or replication, anti-sense sequences which are modified or otherwise, regions for binding to other cellular components, and the like. [0032]
  • “Low molecular weight nucleic acid” as used herein refers to heterologous extrachromosomal pieces of nucleic acid, for example plasmids, having a base length of approximately 2 kb to 20 kb, and in some aspects from 2 kb to 8 kb. In a preferred embodiment, the low molecular weight nucleic acid of the invention comprises a plasmid, where the plasmid has an origin of replication or replicator, a selectable marker and a cloning site. In some instances the low molecular weight nucleic acid is supercoiled. Example plasmids useful in the invention include pUC19, pUC18, pBS2, pEGFP, pBR322, and the like. In addition, low molecular weight nucleic acid is envisioned to encompass other forms of nucleic acid, for example, RNA. [0033]
  • “High quality nucleic acid” as used herein generally refers to nucleic acid associated with a sufficiently low level of contaminants such that it can be digested by appropriate restriction endonuclease enzymes and can be used directly in conventional transformation and transfection procedures, i.e., no further substantial processing of the nucleic acid is required. Preferably, such high quality nucleic acid has a A[0034] 260/280 ratio of from about 1.6 to 2.0 and more preferably from about 1.7 to 1.9. Alternatively and/or additionally, such high quality nucleic acid can be sequenced for up to at least 400 bases using standard sequencing techniques, and more preferably for up to 600 bases, typically having a PHRED score q≧20.
  • “Isolated” and “purified” for purposes of the present invention are interchangeable, and refer to a polynucleotide, for example low molecular weight nucleic acid, that has been separated from cellular debris, for example, high molecular weight DNA, RNA and protein. This would include an isolated RNA sample that would be separated from cellular debris, including DNA. [0035]
  • “Nucleic acid capture matrix” refers to a media or material used for capturing the low molecular weight nucleic acid of the present invention, including, e.g., capture matrix materials typically composed of silica, nylon, carboxy, and the like as well as silica-based beads, including silica-coated magnetized beads. Typically, the capture matrix material of the present invention comprises fiber filters having a pore size of greater than 1 μm, and more typically greater than or equal to 3 μm. The nucleic acid capture matrix or “NA capture matrix” of the present invention may further comprise one or more distinct layers of capture matrix material for capture of the low molecular weight nucleic acid. It should be noted that where multiple layers of matrix material are used, the materials need not be the same in or between each layer of material. In particularly preferred embodiments, the NA Capture Matrix is supported by a frit and incorporated into a conventional spin column or similar device. [0036]
  • “PHRED” or “PHRED score” refers to a software program used to measure DNA sequence quality. The software is purchased from CodonCode Corporation, version 0.020425.c. For purposes of the present invention, a PHRED q20 score of 600 is equivalent to approximately 730 bases at >98.5% accuracy. [0037]
  • “Polyethylene glycols” or “PEGs” useful in the present invention are commercially available diols having a molecular weight of from 2,000 to 10,000 daltons, and more preferably about 8,000 daltons. The use of PEG having other molecular weight constraints, for example higher than 10,000 daltons, is also contemplated for use in the compositions and methods of the present invention, although perhaps not as effective at providing a high yield/quality product. [0038]
  • “Detergent” as used herein refers to any amphiphilic molecule having the property of being inserted into biological membranes and destabilizing them. This results from the capacity of detergent molecules to rupture the membranes by becoming inserted into the phospholipid double layers and by solubilizing the lipids and the proteins (La Cellule, Ed. Vigot and Decarie, 1988, pp. 581-583). [0039]
  • “Zwitterionic” detergent refers to detergents exhibiting zwitterionic character, including for example sulfobetaines sold under the brand names Zwittergent™ and Anzergent™. Particularly suitable detergents are the following: N-dodecyl-N,N-dimethylammonio-3-propane sulfate or the corresponding N-tetradecyl or N-hexadecyl compound (type “Zwittergent”: Zwittergent 3-14, 3-16), N-dodecyl-N,N-dimethyl-glycine (Empigen BB.RTM.), aminoxide, CHAPS, CHAPSO and .alpha.-lecithin (.alpha.-phosphatidylcholin) or .alpha.-lysolecithin (.alpha.-lysophosphatidylcholin). [0040]
  • The invention provides methods and compositions for lysing and solubilizing host cells. In particular, the invention provides a simple three to five minute procedure that utilizes a single solution for lysing and releasing the contents of a cell and contemporaneously solubilizing the majority of the cell's protein. Embodiments of the present invention include methods and solutions for the preferential isolation of low molecular weight nucleic acid, e.g., extrachromosomal DNA, RNA, or other regions of DNA from the host cell, as well as the preferential separation of protein from nucleic acid from a host cell. [0041]
  • In one preferred embodiment, methods and compositions are provided for purifying low molecular weight nucleic acid, for example plasmid DNA, from target host cells. In particular, plasmid DNA is purified from host bacterial cells at high yields and at a quality useful in cloning procedures, restriction digest reactions, and in sequencing reactions. The methods of the invention utilize a single solution to lyse the bacterial cells and bind nucleic acid. Low molecular weight nucleic acid is released from host cells and captured on a nucleic acid capture matrix directly from the crude lysate. The matrix is washed with an appropriate wash buffer and eluted in a final end-use condition. The entire procedure can be performed in less than 10 minutes and in preferred embodiments can be performed in approximately 8 or fewer minutes. [0042]
  • Lysis Solutions: [0043]
  • The invention is based upon, among other things, a lysis solution comprising a buffering ingredient and a detergent. In preferred embodiments, the detergent is a zwitterionic detergent, and in particular a detergent selected from the group that includes, but is not limited to, n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and the like. Note that other zwitterionic detergents are envisioned to be within the scope of the present invention, especially those zwitterionic detergents that have like properties to the enumerated zwitterionic detergents above. Embodiments of this solution are capable of lysing target host cells and solubilizing a majority of the cellular protein. In further preferred embodiments, the lysis solution of the present invention can be used in conjunction with other nucleic acid isolation methods, for example a high concentration of chaotropic salt, to drive the binding of nucleic acid to a solid support matrix. Preferred buffer/detergent embodiments of the solution include lysozyme and either DNase or RNase. [0044]
  • In additional embodiments, it is also contemplated that the above-described lysis solution may further comprise a chelating agent, a salt, polyethylene glycol, lysozyme, and RNase or DNase. As will be appreciated by those of skill in the art, the RNase, for removal of RNA in a DNA purification procedure, or DNase, for removal of DNA in a RNA purification procedure, are technically not required to purify the target nucleic acid using the methods of the present invention, but nucleic acid yield and purity are improved significantly by inclusion of these ingredients. Further, the inclusion of lysozyme has a significant impact on resultant yields, and is particularly preferred as an additional ingredient of the lysis solution of the present invention. Inclusion of these components are contemplated for use in nucleic isolation methods in accordance with the present invention. [0045]
  • In a preferred embodiment, the buffer component of the lysis solution is Tris-Cl having a pH of approximately 8, although other buffering compounds are contemplated. Typically, the final concentration of Tris-Cl in the lysis solution is from about 0 to about 200 mM, and preferably from about 15 to 75 mM. Note that the buffering component of the solution can be modified so that little or no pH modification of the final solution is required. For example, the buffer component can be a combination of Tris-amino and Tris-amino hydrochloride to provide a final lysis solution pH of approximately 7.9 to 8.4. One illustrative combination is to include approximately 17 mM Tris amino with 28 mM Tris amino hydrochloride in the final lysis solution. Other buffering combinations can be used to obtain the appropriate lysis solution pH, which as mentioned above, is optimally from 7.9 to 8.4. [0046]
  • The preferred salt for use in the lysis solution is any common salt used in nucleic acid precipitation, for example, NaCl, NH[0047] 4C1, NH4SO4, MgCl2, and the like. In preferred embodiments, the salt is NaCl, due partly to its availability and relative low cost. Final concentrations of salt in the lysis solution preferably range from 200 to 800 mM and more preferably about 400 mM.
  • The preferred chelating agent for use in the lysis solution is EDTA, but it is contemplated that EGTA can also be used. Final concentrations of EDTA of from 0 to 20 mM, and preferably about 9 mM, are useful in embodiments of the present invention. [0048]
  • The preferred molecular weight of polyethylene glycol (PEG) for use in the present invention is about 2,000 to 10,000 daltons, and more preferably about 8,000 daltons. Typically, final PEG concentration in the lysis solution is from 2 to 20% and preferably from 2 to 8%. Note that PEG is prepared by using techniques well known in the art, for example by heating to an appropriate temperature and filtering to remove particulates. Surprisingly, PEG having higher molecular weight may have deleterious effects on the quality of the purified low molecular weight nucleic acid of the present invention. [0049]
  • Typically, embodiments of the lysis solution include lysozyme, for example egg white lysozyme or recombinant lysozyme, at a final concentration of from approximately 300 to 2,000 μg/ml, and preferably from 800 to 1,200 μg/ml. In addition, RNase (or DNase where the purification target is RNA), for example RNase A, [0050] RNase 1, RNase T1, is preferably included in the Lysis solution at a concentration of from 200 to 400 μg/ml. In both cases, the lysozyme or RNase is stored as a lyophilized powder or in solution. For example, RNase is typically stored in a 100 mM NaCl, 10 mM Tris, and 1 mM EDTA solution. Note that the lysozyme and RNase are required for optimized yield, i.e., full release of the nucleic acid, and removal of RNA contaminants, respectively, and can be included at higher concentrations than disclosed above, but with limited enhancement in yield and quality. Lysozyme, RNase and DNase are commercially available.
  • The lysis solution also includes a detergent at a final concentration of from about 0.2% to 6%, and preferably from about 2 to 4%. Note that lower amounts of detergent can be used in the solutions of the present invention, especially where the concentration of cells being lysed and solubilized is low. Further, although higher levels of detergent are contemplated for use in the present invention, they may not add additional functional value and thus are less preferred. [0051]
  • Typically, the detergent is either an ionic detergent, non-ionic detergent, or a zwitterionic detergent. Typical ionic detergents for use in the present invention include, but are not limited to Deoxycholic Acid. Typical non-ionic detergents for use in the present invention include, but are not limited to, Triton X-100, [0052] Apo 10, Apo 12 and NP40. Typical zwitterionic detergents include, but are not limited to, CHAPS and sulfobetaines, the sulfobetaine detergents sold under the brand name Zwittergent™ and Anzergent™, for example. Note also that in some cases a non-detergent zwitterionic material can also be used, but is not preferred.
  • In preferred embodiments of the present invention the detergent is a Zwitterionic detergent, for example, sold under the brand names Zwittergent™ and Anzergent™, having the chemical names of: n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate. One preferable detergent for use in the present invention is n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate. Note that detergents of the present invention can be purchased under the brand names, for example, of: Anzergent 3-14, Analytical Grade; Anzergent 3-8, Analytical Grade; Anzergent 3-10, Analytical Grade; Anzergent 3-12, Analytical Grade, respectively or zwittergent 3-8, zwittergent 3-10, zwittergent 3-12 and zwittergent 3-14, CHAPS, CHAPSO, Apo10 and Apo12. [0053]
  • Note that it is also envisioned that compatible detergents for use in the present invention can be mixed together to provide the requisite detergent composition (final concentration) for use in the lysis solution. For example, a detergent having a final concentration of 2% in the lysis solution can be composed of a 50:50 mixture of n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate:n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate. [0054]
  • Further, it is envisioned that other constituents can be included in embodiments of the lysis solution, for example, a chaotropic salt at concentrations of between 50 mM and 6M, and preferably between 200 mM and −400 mM, can be included in the solution to assist in the denaturation of proteins. Further, an alcohol, like isopropanol, may be included in the solution at concentrations of between 0.5% to 25%, to assist in the precipitation of the low molecular weight nucleic acid. [0055]
  • During the preparation of the lysis solution, the lysozyme, RNase (or DNase), and detergent should be added after the other components of the solution have been brought to a pH of from 7.9 and 8.4, and preferably to a pH of about 8.1. Where modification of the pH is necessary, any number of well known acids or bases in the art, for example, HCl or NaOH, can be used. [0056]
  • Note also that as discussed above, the pH of the lysis solution should be fairly close to the acceptable range by preparing the solution with the appropriate amounts and compositions of buffering solutions. [0057]
  • The lysis solution is preferably stored at 4° C., although it is envisioned that storage can also be at room temperature. Typically, solutions can be stored for up to 3 months. However, it is also envisioned that the lysis solution in the absence of RNase, DNase, and lysozyme can be stored for up to one to two years. The lysozyme, RNase and DNase may be advantageously added at the time of use from a concentrated solution or as noted above from a lyophilized powder when longer storage times are required. [0058]
  • In a particularly preferred embodiment, the lysis solution is added to target host cells at a temperature of from about 0° C. to 10° C., more preferably 1° C. to 8° C., most preferably 0° C. to 4° C., generally in the range of about 2° C. to 6° C. As used herein, the term “pre-chilled” as used herein refers to the lysis composition of the present invention within the foregoing temperature ranges. As such, when a lysis procedure is anticipated, the lysis solution should be placed on ice for a sufficient period of time prior to use with the host cells to achieve the requisite temperature. [0059]
  • Table 1 provides an illustrative lysis solution for use in the methods of the present invention. [0060]
    TABLE 1
    Illustrative Lysis Solution
    Ingredient Preferred Ingr. Final Conc. Units
    Buffer Tris-Cl (pH 8) 45 mM
    Chelating agent EDTA 9 mM
    Salt NaCl
    400 mM
    PEG MW 8000 8 %
    RNase RNase A 305 μg/ml
    Lysozyme Egg White Lysozyme 1000 μg/ml
    Detergent n-Decyl-N,N- 3 %
    dimethyl-3-ammonio-
    1-propanesulfonate
  • Lysis and Solubilization Method [0061]
  • The methods of the present invention are used to lyse and solubilize target host cells using embodiments of the above-described lysis solution. For purposes of lysing and solubilizing the target cells, the lysis solution comprises a buffering agent and a detergent, preferably a zwitterionic detergent. In particularly preferred embodiments, the lysis solution further comprises lysozyme. The lysis solution can also include other optional constituents as described above, dependent on the anticipated use of the lysed and solubilized material. For example, where isolation of RNA is anticipated, inclusion of DNase is advantageous, or where isolation of a DNA plasmid vector is anticipated, the lysis solution may include RNase. [0062]
  • In a preferred embodiment, the method comprises vortexing or mixing the cells with a pre-chilled lysis solution for a period of from 10 to 30 seconds, followed by a one to ten minute, and more preferably three to five minute, room temperature incubation. This preferred method of the invention provides a compatible procedure to an alkaline lysis procedure, taking less than half the time and generally providing a higher quality product, i.e., cleared lysate. [0063]
  • Lysis Method and Nucleic Acid Purification [0064]
  • The methods of the present invention further include performing a one-solution purification procedure on host cells that harbor target low molecular weight nucleic acid molecules. The procedure results in the isolation of the low-molecular weight nucleic acid, for example plasmid DNA, directly from the lysed cells, i.e., directly from the crude cell lysate. Typically, using the methods and compositions of the present invention, the low molecular weight nucleic acid is released from the host cells, and a substantial majority of the host cellular protein is solubilized by the composition embodiments of the present invention. The released low-molecular weight nucleic acid is captured from the crude cell lysate by a nucleic acid capture matrix, and washed on that matrix in an alcohol-based buffer. The resultant captured low molecular weight nucleic acid is eluted from the capture matrix in an appropriate buffer, typically at a high yield and excellent quality. As such, following the methods of the present invention a single buffer is utilized to lyse the host cell and bind/capture the target low-molecular weight nucleic acid on a solid support, i.e., the nucleic acid capture matrix. The entire process, as more fully described below, can be performed in approximately eight to ten minutes, and requires only standard laboratory equipment. [0065]
  • In more detail, bacterial or other appropriate host cells are transformed with target low molecular weight nucleic acid, as is well known in the art. The host cells are grown to a target concentration (typically 5×10[0066] 8 to 20×108 cells/ml or A600 of between 1 and 4 OD units), harvested, and spun down, as is also well known in the art. The LB growth media (or any other solution on the cells) is decanted off of the cell pellet, and pre-chilled lysis solution (0° C. to 4° C.) of the present invention added to the cell pellet. Typically, approximately 400 μl of lysis solution is added for each 1.5 ml of culture material, although this may be modified to optimize for cell concentration and lysis solution compositions, for example, a lower concentration of detergent can be included in the lysis solution where a smaller number of cells is being treated. Note that in an alternative embodiment of the present invention, the lysis solution is added directed to the cell culture, i.e., prior to the cells being spun down and growth media decanted off of the cell pellet. Typically, a ratio of about 2:1 to about 1:3 cells:lysis solution is combined, the ratio dependent on the cell concentration, embodiment of the lysis solution and other like parameters. Although addition of the lysis solution directly to the cells removes the centrifugation step required for removal of the growth media, it may result in slightly increased protein contamination of the isolated nucleic acid during the lysis purification method, due to the higher levels of potentially contaminating material in the starting material. Nevertheless, where such contaminants are of less concern or time is of the essence the present invention enables a further reduction in the requisite handlings steps.
  • The lysis solution, the composition of which is discussed in greater detail below, is continuously vortexed or mixed on the host cells for approximately 10 to 30 seconds, and more preferably for about 20 seconds. The re-suspended cell mixture is next incubated at room temperature for a period of from one to ten minutes, and more preferably from three to five minutes, and most preferably about five minutes. The room temperature incubation results in the substantial release of the low-molecular weight nucleic acid from the host cells and the solubilization of a substantial portion of the host cellular protein. Note, shorter lysis solution room temperature incubations can be used in conjunction with the present invention, although the yield of low molecular weight nucleic acid is correspondingly lower. In addition, longer room temperature lysis incubations may be used, but little improvement in low molecular weight nucleic acid yield or quality is typically observed beyond the five to ten minute incubation. [0067]
  • The inclusion of the pre-chilled lysis buffer on the host cells, and subsequent room temperature incubation, provides a temperature gradient during which host cell proteins are solubilized by the lysis buffer. Without being bound by theory, it is believed that this aspect of the present method takes advantage of different cellular proteins solubility over a range of temperatures (from 0° C.-4° C. to room temperature) and to some extend pH changes (due to the temperature change of the buffer). However, it is envisioned that lysis buffer temperature and host cell incubation temperature can be modified in relation to the methods of the present invention, with some effect on the overall yields and purity of low molecular weight nucleic acid. [0068]
  • After the room temperature incubation, the released low molecular weight nucleic acid and solubilized cellular debris is transferred to a spin column having at least one layer of nucleic acid (NA) capture matrix (preferred embodiments can have a second and/or third layer of NA capture matrix incorporated into the spin column). The above mixture is spun through the spin device at approximately 14,000 RPM (20,000×G) for approximately 30 seconds using a mini- or micro-centrifuge (one of skill in the art will recognize that other speeds and times can be used in the context of the present invention as long as the fluid is pulled through the spin column, as is well known in the art). Note that other procedures can be used in this aspect as well, for example vacuum filtering and the like of the material through the nucleic acid capture matrix. [0069]
  • In an alternative embodiment, NA capture matrix material is included directly in the lysis buffer and added directly to the host cells during the room temperature lysis buffer/host cell incubation. In such cases, the lysis buffer/nucleic acid capture matrix must be thoroughly mixed before addition to the host cell pellet so that the matrix is thoroughly re-suspended. [0070]
  • The NA capture matrix binds a portion of the released low molecular weight nucleic acid from the cellular debris, i.e., crude lysate. Surprisingly, nucleic acid capture matrix with a pore size of greater than 1-2 μm is preferred for use in the invention, and preferably, multiple layers of nucleic acid capture matrix, each having pore sizes of at least 1-2 μm is used during capture of the low molecular weight nucleic acid. Note that matrix materials having pore sizes of less than 1-2 μm are also envisioned for use in the present invention, but display a tendency to become clogged and require additional processing not necessary with the larger pore materials. In addition, the larger pore materials preferred for use herein tend to provide superior capture characteristics in conjunction with the invention not present in smaller pore materials [0071]
  • In order to maximize the purity of the captured low molecular weight nucleic acid, one or more wash steps is performed on the loaded nucleic acid capture matrix. The wash buffer is typically a 20 mM Tris-Cl, pH of 7.2, 0.2 M NaCl, and 2 mM EDTA, pH of 8.0)/isopropanol solution. Typically, the ratio of Tris buffer:Isopropanol is about 30-35:70-65, and is preferably about 32.5:67.5 (note that other like alcohols can be used in place of isopropanol, for example ethanol). Note that other wash buffer compositions can be used with the present invention as long as they preferentially dissociate contaminants to low molecular weight nucleic acid from the capture matrix. The wash step removes loosely associated protein and other macromolecules from the loaded nucleic acid capture matrix. [0072]
  • Finally, the low-molecular weight nucleic acid is eluted from the NA capture matrix using a 10 mM Tris, 0.1 mM EDTA solution, having a pH of approximately 8.5. Typical elution parameters include using smaller volumes to maintain a higher concentration of the target low molecular weigh nucleic acid, and minimizing the amount of EDTA or other enzyme inhibitory constituents in the elution buffer. [0073]
  • As illustrated with the above elution buffer, elution of the low molecular weight nucleic acid can be performed in a solution compatible with the end-use application, for example, using an elution buffer having little inhibitory activity on polymerase enzymes. As such, the end-use application can be performed directly on the eluted sample without having to precipitate and re-suspend the nucleic acid in the appropriate buffer. Other elution buffer solutions for use in the present invention include water, TE buffer, 10-50 mM Tris buffer, and the like. [0074]
  • Nucleic Acid Capture Matrix: [0075]
  • A number of different nucleic acid capture matrix compositions are useful in conjunction with the methods and compositions of the present invention for capture of low molecular weight nucleic acid. Capture matrix compositions for use in the present invention include silica-, nylon-, and acrylic-based materials. Typical pore sizes for the filter capture matrix material are from 1 to 25 μm, and preferably from 1 to 5 μm, and most preferably from 3 to 5 μm. It is noted that matrix materials having larger pore sizes can be used in conjunction with the present invention, but are likely less effective in capturing low molecular weight nucleic acid. In addition, smaller pore size capture matrix materials, i.e., smaller than 1 μm, can also be used in conjunction with the present invention, but tend to clog during the capture process (note that matrix materials having pore sizes of between 1 and 2 μm can also show some level of clogging, dependent on the number of matrix layers and size of sample). [0076]
  • In preferred embodiments, a first layer of capture matrix material is incorporated into a spin device as is well known in the art. The capture matrix material will be of a composition and pore size compatible with the parameters previously described, but is preferably a glass fiber having a pore size of between 3 to 5 μm. In some embodiments, the spin device includes two layers of capture matrix material, for example, a first (top) layer of material having a pore size of approximately 5 μm and a second layer (lower) of capture matrix material having a pore size of approximately 3 μm. The additional capture matrix material provides an additional surface area/support for the capture of the target low-molecular weight nucleic acid. Typically, the two layers are of different materials, although it is envisioned that the two layers can be the same material. Further, pore size between layers is typically different, with the larger pore size material on top of the smaller pore size material. Finally, additional capture matrix material layers may be added, although clogging of the filter material may become a greater concern. [0077]
  • Note that a frit may be included in the NA capture matrix, below the one or more capture matrix material layers for support. A typical frit is composed of an inert material, for example polyethylene, having a pore size of between 5 to 70 μm. [0078]
  • In an alternative embodiment, a portion, for example 350 μl of NA capture matrix slurry, e.g., a silica bead in solution, is deposited directly into the lysis solution/host cell material and incubated for a short period of time (typically with vortexing or other mixing technique). The capture matrix slurry/lysis solution mixture is spun down as above, and the pelleted matrix washed with an appropriate wash buffer. As above, the captured low molecular weight nucleic acid is released in an appropriate elution buffer. In addition, silica coated magnetized beads can be utilized as the NA capture matrix. The use and preparation of these beads is described in U.S. Pat. No. 6,368,800, which is incorporated herein by reference. Use of the silica coated magnetized beads obviates the need for centrifugation steps during the purification of target nucleic acid. [0079]
  • Table 2 provides illustrative NA capture matrix materials with corresponding pore sizes as well as several commercially available spin devices. [0080]
    TABLE 2
    NA Capture Matrix Materials
    NA Capture Matrix Source
    Glass Fiber Ahlstrom 141, 142
    Whatman GF/C, GF/D
    Nylon Pall Biodyne
  • Automation of Lysis Method: [0081]
  • The methods and compositions of the present invention are useful in the isolation of high-yield and high-quality low molecular weight nucleic acid from target host cells during high throughput applications. [0082]
  • The methods of the present invention can be performed on one sample at a time using standard laboratory equipment and personnel. However, due to the limited number of steps/compositions required to perform the methods of the present invention, and due to the limited level of complexity of those steps, it is envisioned that the methods be utilized in a highly automated procedure for isolating target nucleic acid samples from a plurality of discretely handled samples. [0083]
  • In particular, the compositions and methods of the present invention can be used in a multi-well, for example 96 or 384 well, protocol. Cells are grown in the appropriate number of wells required for the particular procedure. After appropriate cell growth, the cells are pelleted using a multi-well plate centrifuge. Each cell sample in the multi-well plate is re-suspended in approximately 400 μl of pre-chilled lysis solution. Plates are shaken, or each wells constituents pipetted using a multi-channel pipette or 96-pin head, in order to re-suspend the cells completely. Samples are incubated for approximately 3 to 5 minutes at room temperature. Using the multi-channel pipette or 96-pin head, the lysate from each well is transferred to a corresponding multi-well filter plate. The lysate is vacuumed through the filter matrix (same types of capture matrix formats as discussed above) to capture the low-molecular weight nucleic acid on the capture matrix. Again using the multi-channel pipette or 96-pin head, approximately 400 μl of wash buffer is added to each well of the filter plate. Wash buffer is pulled over the capture matrix to remove residual protein and nucleic acid, and the vacuum is pulled until much of the residual alcohol is removed from the captured low-molecular weight nucleic acid. Appropriate plates are prepared for receiving the eluted low-molecular weight nucleic acid, and elution performed on each sample. This process of forcing liquids through the filter plate can also be performed using centrifugation. Note that centrifugation should be avoided during the automation process where the process is being performed on a automation workstation. [0084]
  • Finally, note that the automation procedures of the present invention can be performed using silica coated magnetized beads. The purification steps would be substantially the same as above, except that the NA capture matrix would be separated from the lysate using the magnetic properties of the beads and would not require a centrifugation step. [0085]
  • This process can be automated into a high-throughput procedure using pre-calibrated equipment. Other methods are envisioned for high-throughput operations and are not limited to 96-well or 384-well plates. As such, the methods of the present invention are ideal for the automated preparation of a large number of discrete high quality low molecular weight nucleic acid samples. [0086]
  • Low Molecular Weight Nucleic Acid Purification Kit [0087]
  • Embodiments of the present invention provide kits for the performance of the above described nucleic acid purification/isolation methods. In one embodiment of the present invention, the kit includes a lysis solution and NA capture matrix material (either as a spin column or matrix slurry). A preferred embodiment the kit further includes an elution solution and wash buffer. The kits of the present invention can also include molecular biology grade water, collection tubes, 384 well plates (optionally incorporating NA capture matrix), 96 well plates (optionally incorporating NA capture matrix), pipette tips, microcentrifuge, protective gloves, etc. [0088]
  • For maximum stability, the kits can contain lyophilized lysozyme, RNase and/or DNase that can be added to the lysis solution at the time of the kits first use. In some embodiments the detergent can also be provided separately for addition to the other ingredients just prior to use. [0089]
  • Finally, in some kits it is envisioned that a plurality of tubes used in the culture of cells, for example the Lid-Bac tube (U.S. Pat. Nos. 5,958,778 and 6,503,455, incorporated herein by reference), can also be included. These tubes would allow for the culture of target cells and the processing, lysis and solubilization of those same cells to be accomplished all in a single tube, using the lysis solution and methods of the present invention. The target nucleic acid is then isolated in that same tube by addition of a nucleic acid capture matrix slurry or in a second tube, for example a spin device having a layer of nucleic acid capture matrix directly incorporated therein. [0090]
  • Binding Solution: [0091]
  • In an alternative embodiment in accordance with the present invention, a solution that includes a buffer, PEG, and salt is used to preferentially bind nucleic acid from a cleared lysate to a silica fiber. A preferred binding solution includes from 1 to 20% PEG having a molecular weight of from 2,000 to 10,000 daltons; from about 100 to 2000 mM salt, for example NaCl; from about 10 to 200 mM buffer, for example, Tris. NA capture matrix for use with this binding buffer includes silica beads and fibers. Preferred silica fibers have pores of from 1 to 20 μm, and more preferably from 3 to 5 μm. [0092]
  • Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting. [0093]
  • EXAMPLES Example 1 Preparation of Lysis Solution
  • Table 3 provides the composition of one potential lysis solution of the present invention. The concentration of each constituent is addressed for the amount of weight per liter of solution. [0094]
    TABLE 3
    Lysis Solution
    Ingredient Concentration Amount W or V per Liter
    Polyethylene Glycol-8000 8.02% 80.23 g
    NaCl   401 mM 23.45 g
    Tris Amino  17.3 mM  2.11 g
    Tris Amino Hydrochloride  28.5 mM  4.47 g
    6.6M Guanidine  85.5 mM 15.09 g
    Hydrochloride
    Guanidine Thiocyanate  70.3 mM  8.31 g
    n-Decyl-N,N-dimethyl-3- 3.05% 30.55 g
    ammonio-1-
    propanesulfonate
    0.5M EDTA  9.2 mM 19.98 g
    RNase A   305 μg/ml   305 mg
    UF water N/A   870 g
    1N NaOH N/A as required
    1N HCl N/A as required
    Egg White Lysozyme  1000 μg/ml  1000 mg
  • Example 2 Room Temperature Incubation Increases Recovery of High Quality Plasmid DNA
  • The following Example illustrates that a three to ten minute room temperature incubation, and preferably a five minute room temperature incubation, of the lysis buffer on plasmid containing bacterial cells is beneficial for high yield recovery of high quality plasmid DNA. [0095]
  • Bacterial host cells were transformed with pUC19 plasmid and grown in 96 well plates overnight as is well known in the art. Plates were thawed for 15 minutes at room temperature, and approximately 400 μl of previously described Lysis buffer added per well of each plate. Note that the Lysis buffer was pre-chilled to 0° C. before addition to the bacterial cultures. [0096]
  • Cultures were then either immediately spun down, or re-suspended on a plate shaker, and incubated for a varying amounts of time at room temperature. Each lysate, having a varied 0 to 10 minute room temperature incubation, was removed and transferred to a silica based NA capture matrix and spun down at 14000 RPM for one minute. The resultant filtrate was removed from each well, and the NA capture matrix washed with a wash buffer solution (20 mM Tris-Cl pH 7.2, 0.2 M NaCl, 2 [0097] mM EDTA pH 8, 75% isopropanol). The wash buffer was spun off at 14000 RPM for one minute. Elution of the captured pUC19 from the NA capture matrix was performed using 50 μl elution buffer (10 mM Tris-Cl and 0.1 mM EDTA), and each elution sample tested for pUC19 yield and protein contamination.
  • Referring to FIG. 1A, isolated plasmid DNA from each incubation condition was run on a 0.5% agarose gel. The ethidium bromide stained gel shows that all incubation conditions provided a good yield of plasmid DNA, including the immediate spin condition. FIG. 1B and Table 4 provide a graphical and tabular illustration of each sample's concentration and A[0098] 212 value in relation to the incubation time. Note that as room temperature incubation period proceed, the protein contamination in the sample decreased until about three minutes, at which time the protein and nucleic acid concentrations in the sample stabilize. Taken together, FIGS. 1A and 1B illustrate that a room temperature incubation of Lysis buffer on the target cells decreases the protein contamination of the isolated pUC19 while not adversely affecting the yield of the plasmid. This Example shows that a three to ten minute, and preferably a five minute, room temperature incubation of the Lysis on the host cells is useful for maximizing resultant low-molecular weight nucleic acid yield and purity. In addition, shorter incubations, zero to two minutes, appear to not fully allow for the contaminants to be separated from the target nucleic acid using the solutions and methods of the present invention. Note that the high concentration of DNA of short incubation times, as determined by absorbance readings, are inflated due to contamination and do not represent the actual concentrations. The concentrations shown for incubation times greater than or equal to three minutes are representative of the true concentration of the isolated DNA.
    TABLE 4
    Plasmid Yield and Protein Contamination With Varying Room
    Temperature Incubation
    R.T. Incubation A260/280 Ave. Concentrationa Ave A212
    Immediate spin 1.86 440 14.12
     1 min 1.83 426.4 15.9
     2 min 1.84 318 13.4
     3 min 1.86 184.7 7.27
     4 min 1.75 247.7 13.4
     5 min 1.84 150.8 7.14
     7 min 1.87 166.3 6.6
    10 min 1.8 174.1 8.8
  • Example 3 Detergent Type and Concentration is Critical for Lysis Buffer Effectiveness
  • Methods and solutions used to transform bacterial host cells with nucleic acid as well as grow transformed cells for isolation of the nucleic acid are well known in the art. Further, the inventive methods used to purify the plasmid DNA from bacterial host cells are essentially the same as shown in Example 2 above, with the exception that the detergent type in the lysis buffer was varied to determine which types of detergents are most useful in the present context. [0099]
  • With regard to the lysis buffer conditions used in this Example, a standard lysis buffer was prepared having: [0100]
  • 50 mM Tris-Cl (pH—8); [0101]
  • 10 mM EDTA (pH—8); [0102]
  • 350 μg/ml RNase; [0103]
  • 1200 μg/ml Lysozyme; [0104]
  • 7.5% PEG-8000; [0105]
  • 1% detergent (type varied according to the sample); [0106]
  • 50 μl/ml glass matrix beads; and [0107]
  • 0.75 M NaCl. [0108]
  • A series of 12 different lysis buffers was prepared using this base composition above, each having a different type of detergent added to a final concentration of 1%. In particular, the detergents were (1) N,N′,N′-Polyoxyethylene(10)-N-tallow-1,3-diaminopropaned (N,N,N-PTD), (2) NDSB-195, (3) NDSB-201, (4) NDSB-256, (5) Apo-10, (6) Apo-12, (7) CHAPS, (8) n-Octyl-B-D-glucopyranoside, (9) De-Oxcholic Acid, (10) SDS, (11) Triton X-100 mixed with SDS (50:50), and (12) Triton X-100. Note that the lysis buffer can be brought to a pH of 8.5 in the absence of the RNase, lysozyme and detergent. As shown in FIG. 2, the type of detergent used in the lysis buffer had a dramatic effect on both the yield and quality of the purified plasmid DNA. For example, the inclusion of N,N,N-PTD detergent resulted in a high yield/high quality one-step plasmid preparation, whereas under the exact same conditions, the inclusion of De-oxcholic Acid provided adequate yield of plasmid DNA, but lower quality purified plasmid DNA. As such, detergent type had a profound effect on resultant yield and quality. [0109]
  • A further series of experiments were performed using zwitterionic detergents to determine their effectiveness for use in the lysis buffer. In general, zwitterionic (zw) detergents were used at concentrations of between 1 to 4% to determine whether all or specific types of zwitterionic detergents are effective in the methods of the present invention. Interestingly, the zwitterionic detergents n-ocytl-N,N-dimethyl-3-ammonio-1-propanesulfonate (zw-8), n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (zw-10), n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (zw-12) and n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (zw-14) all showed either adequate (zw-8) or good results (zw-10, zw-12 and zw-14) (data not shown). [0110]
  • To further define the effectiveness of the zwitterionic detergents in lysis solutions, detergents were incorporated into the same lysis solution (zw-10, zw-12 and zw-14) alone, or in mixtures, at final concentrations that varied between 1% and 4%. Table 5 illustrates a summary of these results showing that zwitterionic detergents, present at from 1 to 4%, are excellent for high yield and purity isolation of low molecular weight nucleic acid from host cells. Data from lysis solutions using NP40 or Qiagen kit purified DNA were included for comparison. [0111]
    TABLE 5
    Zwitterionic Detergent Concentration
    And Type Effect Yield and Purity of Target Nucleic Acid
    Concentration
    Detergent Type A260/280 ng/μl A212
    Varying ZW 3-12 and 3-14 From 1 to 4%
    1% ZW 3-12 1.88 299.9 7.24
    2% ZW 3-12 1.90 318.0 7.44
    3% ZW 3-12 1.86 319.8 7.43
    4% ZW 3-12 1.87 374.8 9.06
    1% ZW 3-14 1.86 384.2 9.02
    2% ZW 3-14 1.89 397.0 9.34
    3% ZW 3-14 1.84 393.1 9.52
    4% ZW 3-14 1.81 425.2 9.63
    3% NP40 1.90 442.7 11.47
    Varying ZW 3-10 and 3-12 and Mixtures of Both From 2 to 3%
    2% ZW 3-10 1.85 313.8 8.94
    3% ZW 3-10 1.85 355.1 9.62
    2% ZW 3-12 1.86 369.7 9.86
    3% ZW 3-12 1.87 377.0 9.35
    1.5% ZW 3-10/ 1.87 370.5 9.77
    1.5% ZW 3-12
    1.5% ZW 3-10/ 1.89 375.1 10.08
    1.5% ZW 3-14
    1.5% ZW 3-12/ 1.85 416.65 10.98
    1.5% ZW 3-14
    1% ZW 3-10/ 1.88 340.28 9.31
    1% ZW 3-12/
    1% ZW 3-14
    Qiagen 1.84 174.38 4.97
    Varying Detergent Type With Temperature or Incubation Time
    3% ZW 3-10/ 1.91 254.61 8.19
    RT
    3% ZW 3-10/ 1.84 137.87 5.34
    4° C.
    3% ZW 3-10/ 1.82 110.7 4.44
    on ice
    3% ZW 3-12/ 1.99 455.58 13.24
    RT
    3% ZW 3-12/ 1.99 319.47 9.15
    4° C.
    3% ZW 3-12/ 1.94 198.80 6.02
    on ice
    3% ZW 3-14/ 1.97 235.57 7.60
    RT
    3% ZW 3-14/ 2.0 516.83 14.58
    4° C.
    3% ZW 3-14/ 1.94 198.80 6.02
    on ice
    3% ZW 3-10/ 1.74 129.67 11.65
    2 minutes
    3% ZW 3-10/ 1.84 127.86 5.20
    5 minutes
    3% ZW 3-12/ 1.92 270.66 10.32
    2 minutes
    3% ZW 3-12/ 1.95 171.93 5.33
    5 minutes
    3% ZW 3-14/ 1.96 379.94 11.96
    2 minutes
    3% ZW 3-14/ 1.89 217.09 7.67
    5 minutes
    Qiagen control 1.91 88.66 2.02
  • Example 4 Pre-Chilled Lysis Solution Enhances Quality of Purified Nucleic Acid
  • The lysis methods and solutions of the present invention were used to evaluate the effect of adding different temperature lysis solutions to pUC19 transformed DH5α cells. The quality of the isolated pUC19 was determined as above. [0112]
  • Methods and solutions used to transform cells with pUC19, and to grow transformed cells in anticipation of isolation of the pUC19 are well known in the art. Lysis solution as described in the Examples above was prepared having either a detergent composed of 3% zw 3-10, 3% zw 3-12, or 3% zw 3-14. Lysis solutions for each detergent condition were either left at room temperature, chilled to 4° C. or chilled to about 0° C. before addition to the cells. Results in Table 6 and FIG. 3 illustrate that the DNA isolated using the chilled lysis solutions (4° C. and 0° C.) provided higher quality isolated DNA than the DNA isolated using the lysis solution at room temperature. Lanes 3-18 in FIG. 3 show that the yield from each detergent type, at each temperature, was about the same (2 μl of each sample run per lane), conversely the absorbance readings from the same samples indicated that the isolated pUC19 using room temperature lysis solution, regardless of detergent type, had higher level of protein contaminants (see Table 6). [0113]
    TABLE 6
    Temperature of The Lysis Solution Effects NA Quality
    Sample Type A260 A280 A260/280 Conc. ng/μl A212
    zw 3-10, RT 0.255 0.133 1.91 254.6 8.19
    zw 3-10, 4° C. 0.138 0.075 1.84 137.9 5.34
    zw 3-10, 0° C. 0.111 0.061 1.82 110.8 4.44
    zw 3-12, RT 0.456 0.229 1.99 455.6 13.2
    zw 3-12, 4° C. 0.320 0.160 1.99 319.5 9.2
    zw 3-12, 0° C. 0.199 0.103 1.94 198.8 6.0
    zw 3-14, RT 0.236 0.119 1.97 235.6 7.6
    zw 3-14, 4° C. 0.517 0.259 1.99 516.8 14.5
    zw 3-14, 0° C. 0.205 0.102 2.1 204.5 6.1
  • This data generally illustrates that pre-chilled lysis solution provides for higher quality isolated plasmid DNA as compared to identical lysis solutions added to the cells at room temperature. Note, however, that lysis solution added to the cells at room temperature did provide isolated plasmid DNA, and that the isolated plasmid DNA was of a reasonably good quality. [0114]
  • Example 5 Matrix Material and Pore Size of Nucleic Acid Capture Matrix is Critical for High Yield and Quality Isolation
  • The lysis methods of the present invention were used to evaluate a number of filter membrane substances, having different compositions and pore sizes, for effectiveness in isolating high quality low molecular weight nucleic acid. Both filter type and pore size were investigated for effectiveness at isolating high yield and high quality low-molecular weight nucleic acid. [0115]
  • The procedure for releasing the low molecular weight nucleic acid from target host cells was as described above. Briefly, target low molecular weight nucleic acid was propagated in target host cells in 96-well culture plates. Host cells were grown to a predetermined concentration, and cells spun down and growth media removed. Approximately 240 μl of pre-chilled lysis solution was added to each well and the cells re-suspended on a plate shaker for two minutes at a seven setting. [0116]
  • Filter conditions were varied in wells of filter plates, where wells in each plate had one of six filter combinations, which were prepared as follows: [0117] Sample 1 included a two layer NA capture matrix: layer one (top) was a glass fiber layer (1.2 μm pore size), layer two (middle) was a glass fiber (0.8 μm) and the frit was polyethylene; sample 2 included the same combination as sample one except the frit was hydrophobic; sample 3 included two layers, a first layer of 23 μm glass fiber filter on top of a frit having a pore size of 25 μm; sample 4 included a 11 μm glass fiber filter/polypropylene 25-30 μm combination; sample 5 included a 20 μm/11 μm glass fiber filters on a polypropylene 25-30 μm combination and sample 6 included a 7 μm glass fiber filter on a polypropylene 25-30 μm combination.
  • The results in Table 7 illustrate that, unlike conventional isolation techniques, the present invention provides optimal results with capture matrix having pore sizes that are generally greater than about 1 μm. Best results in the present Example were seen using the matrix combinations in [0118] samples 3 and 5, indicating that a 20 μm glass fiber filter over 11 μm glass fiber filter and a 23 μm glass fiber filter provided good low molecular weight nucleic acid capture and release characteristics for use in the present invention.
    TABLE 7
    NA Capture Matrix Results
    Sample A260/280 Concentration ng/ml A 212
    1 1.45 370.7 36.6
    2 1.36 4.89 0.31
    3 1.88 290.9 11.0
    4 1.48 426.9 46.7
    5 1.88 879.9 32.2
    6 1.78 213.2 9.4
  • A second series of experiments were performed using XL1 Blue/pUC19 grown in 1.5 ml host cell cultures and 400 μl lysis pre-chilled solution. Samples were incubated with lysis at room temperature for 5 minutes. Fourteen different capture matrix combinations were tested as follows: (1) Pallflex U100z Med. (rough side-up); (2) S&S GF#25; (3) Pallflex 2500-S2608G (smooth side-up); (4) Pallflex 2500-S2608G (rough side-up); (5) Pallflex 2500 AE 53009M (smooth side-up); (6) Pallflex 2500 AE 53009M (rough side-up); (7) Whatman GMF 934AH; (8) Whatman GMF 150 2 μm (two layers of same pore size); (9) Whatman 150 2 μm (top layer only); (10) 20 μm PE frit with a 5 μm GF layer; (11) one layer of 5 μm GF; (12) S&S GF number 24 (smooth side-up); (13) 23 μm glass fiber filter (Ciro) and (14) 23 μm glass fiber filter (Ciro) with a standard buffer. [0119]
  • Resultant isolated plasmid DNA was tested for concentration and quality as well as for use in sequencing reactions. (see Tables 8 and 9). Results indicate that glass fiber and larger pore size samples are good candidates for nucleic acid capture matrix. [0120]
    TABLE 8
    NA Capture Matrix Concentration, A260/280, and A212 Results
    Sample A260/280 Concentration ng/ml A 212
    1 1.69 60.3 6.14
    2 1.97 76.8 2.94
    3 1.76 71.3 3.40
    4 1.70 63.23 2.8
    5 1.75 75.4 2.93
    6 1.81 83.55 3.4
    7 1.81 234.5 10.88
    8 1.83 174.4 6.0
    9 1.64 125.2 4.3
  • [0121]
    TABLE 9
    Sequencing Quality Of Isolated Low
    Molecular Weight Nucleic Acid
    Sample Mean Std. Dev. Std. Error Count Min. Max.
    1 582.57 38.46 14.54 7 530 624
    2 588.71 30.86 11.67 7 554 628
    3 603.57 38.07 14.39 7 553 647
    4 632 22.48 9.2 6 594 663
    5 591.6 30.16 13.49 5 571 645
    6 607.1 18.24 6.90 7 581 631
    7 544.1 86.76 32.79 7 372 620
    8 649.14 12.95 4.90 7 627 662
    9 580.17 124.7 50.9 6 333 659
    10 642.83 44.89 18.33 6 591 691
    11 616.17 72.93 29.77 6 531 686
    12 596 56.19 22.94 6 529 686
    13 Not
    Tested
    14 Not
    Tested
  • A third series of experiments is shown in Table 10 and FIG. 4 where both NA capture matrix material and pore size were tested for capacity for isolating plasmid DNA from a bacterial host cell source. Bacterial host cells harboring XL1Blue/pBS2 were harvested and treated with lysis solution as previously described in the Examples above. Similarly treated samples were contacted to either a nylon, PVDF or glass fiber filter having pore sizes as described: (1) 0.45 μm Nylon fiber, (2) 1.2 μm Nylon fiber, (3) 5.0 μm Nylon fiber, (4) Pallflex® Emfab filter with 70 μm frit, (5) 0.45 μm PVDF, (6) 1.0 μm Glass fiber filter, (7) two layers of 1.2 μm glass fiber filters, (8) 23 μm glass fiber filter. (9) 5 μm glass fiber filter over a 3 μm glass fiber filter over a 20 μm frit. [0122]
  • FIG. 4 indicates that although isolation of the plasmid DNA using either nylon or Pallflex yielded adequate results, the glass fiber material, and in particular the two layers of glass fiber material in [0123] sample 9 provided for an excellent NA capture matrix in the context of the present invention. As shown in Table 10, the quality of the isolated plasmid DNA showed good A260/A280 ratios and A212 readings, especially with regard to sample 9—the two layer glass fiber capture matrix having a first layer with a pore size of 5 μm and the second layer having a pore size of 3 μm.
    TABLE 10
    Plasmid DNA Quality
    Sample Number A230/A280 Concentration μg/ml A212
    1 N/A - clogged
    2 1.67 42.5 2.45
    3 1.76 51.8 4.21
    4 1.68 21.6 2.0
    5 N/A - clogged
    6 1.74 80.7 4.56
    7 1.72 90.8 5.3
    8 1.71 88.4 3.6
    9 1.83 202.0 8.0
  • Example 6 Methods and Compositions of the Present Invention are Useful with a Number of Different Host Cells and Target Low Molecular Weight Nucleic Acids
  • The data in the following Example illustrates that the lysis solutions are useful for the isolation of different sized plasmid DNA from several different host cells. Host cell/vector combinations were grown in LB/amp media overnight for 14 to 16 hours. Each cell condition consisted of 1.5 ml of pelleted culture, which was processed with 400 μl lysis solution (see Example 1). Data shown in Table 11 and FIG. 5, illustrate that the present methods and compositions are useful with a number of different host cells and different plasmids. [0124]
    TABLE 11
    Plasmid DNA From Different Host Cells
    Ave PHRED
    Host Cell/Vector A260/280 Concentration ng/ul A212 Q20
    JM110/pUC18 1.83 69.3 4.1 567
    DH5α/pUC19 1.92 150.8 6.2 524
    Top10/pEGLYSIS 1.88 247.2 6.9 NA
    HB101/pUC19 1.86 133.1 5.7 516
    DH5α/pBS2 1.86 122.9 5.4 552
    Top10/β-gal 1.88 394.3 10.4 588
    XL2blue/pBS2 1.87 164 6.4 586
    Top10/β-gal NA NA NA 584
    (Qiagen prep)
  • Example 7 Purified Low Molecular Weight Nucleic Acid can be Used Directly in PCR Reactions
  • Purified low molecular weight nucleic acid may be directly amplified in a PCR reaction after recovery from the host cell using the methods and compositions of the present invention. Bacterial cells having a pGEM clone from a mouse cDNA library were treated using the methods and solutions of the present invention, and isolated pGEM was used directly in a PCR reaction, i.e., no additional steps performed on the pGEM after its elution off of the NA capture matrix of the present invention. The PCR reaction incorporated a T7 and a Sp6 primer and was performed using PCR methods well known in the art. [0125]
  • As shown in FIG. 6, the pGEM DNA isolated using the methods and compositions of the present invention was an excellent template for PCR. This data indicates that the present invention provides quality DNA that can be directly used in PCR, importantly, the DNA does not require additional manipulation for its use in these reactions. [0126]
  • Example 8 Plasmid DNA can be Isolated in a 96-Well Format Using the Methods and Compositions of the Present Invention
  • Bacterial host cells having a pUC19 plasmid were grown in 96-well plates to determine whether the methods and compositions of the present invention are applicable to high throughput applications. [0127]
  • Cells were grown and spun-down as described above, except that cells were grown in the wells of a 96 well plate and pelleted using a plate centrifuge. Approximately 400 μl of pre-chilled lysis solution was added to each well. Plates were either shaken, vortexed or each well individually pipetted up and down to thoroughly mix the cells in the lysis solution. A five minute room temperature incubation followed and the DNA eluted and analyzed. As shown in Table 12, plasmid DNA isolated from host cells grown in 96 well plates showed good quality and yield. Note that the plasmid DNA was captured in 96 well filter plates where each well has a pair of glass fiber layers having 5 μm and 3 μm pore sizes, the NA capture matrix on a 7 μm frit. [0128]
  • The data in this Example illustrates that the methods and compositions of the present invention are adaptable to high throughput applications, for example, 96-well format plates. Further the data indicates that mixing the cells with lysis solution can be accomplished by shaking the plates on a plate shaker, vortexing the plates on a plate vortex or pipetting the contents of each well using a 96 well pin. [0129]
    TABLE 12
    Data From 48 Wells of a 96 Well Plate
    Well Number A260/A280  Concen. μg/ml A212  Mixing Step 
    A7 1.8 331.9 16.2 Shaken
    B7 1.8 302.5 14.6 s
    C7 1.8 284.0 13.5 s
    D7 1.8 252.2 12.3 s
    E7 1.8 252.2 11.8 s
    F7 1.8 294.1 14.0 s
    G7 1.8 249.2 11.3 s
    H7 1.8 248.7 11.1 s
    A8 1.8 351.6 17.1 Shaken
    B8 1.8 294.4 14.2 s
    C8 1.8 301.2 13.8 s
    D8 1.8 281.4 14.5 s
    E8 1.8 269.4 12.4 s
    F8 1.8 267.9 13.2 s
    G8 1.8 262.0 12.1 s
    H8 1.8 292.5 12.3 s
    A9 1.8 257.7 11.4 Vortex
    B9 1.8 249.7 11.5 v
    C9 1.8 275.2 12.7 v
    D9 1.8 259.3 12.8 v
    E9 1.8 277.8 13.0 v
    F9 1.8 276.8 13.5 v
    G9 1.8 239.7 11.8 v
    H9 1.8 281.4 12.3 v
    A10 1.8 252.8 11.8 Vortex
    B10 1.8 241.4 11.4 v
    C10 1.8 226.7 10.7 v
    D10 1.8 223.6 12.0 v
    E10 1.8 248.8 14.5 v
    F10 1.8 270.2 15.5 v
    G10 1.8 261.6 15.3 v
    H10 1.8 286.9 14.0 v
    A11 1.8 209.1 13 Pipette
    B11 1.8 187.4 10.2 p
    C11 1.8 239.2 14.6 p
    D11 1.8 277.1 28.2 p
    E11 1.8 261.2 24.0 p
    F11 1.8 299.1 30 p
    G11 1.8 284.9 27.3 p
    H11 1.8 342.0 38.2 p
    A12 1.8 234.1 14.6 Pipette
    B12 1.8 225.0 13.4 p
    C12 1.8 222.5 14.4 p
    D12 1.8 301.3 28.0 p
    E12 1.8 307.9 32.6 p
    F12 1.7 343.1 42.0 p
    G12 1.7 314.6 40.3 p
    H12 1.7 313.7 40.6 p
  • Example 9 Quality of Plasmid DNA Purified Using the Methods and Compositions of the Present Invention are Comparable to Other Conventional Plasmid DNA Purification Methods
  • Two to five milliliters of culture (Top10 cells/pSV-β-gal) from a streak LB agar plate were grown overnight to reach a desired cell density. Growth was performed in 15 ml conical tubes. Approximately 1.5 mls of cells was harvested and pelleted and processed according to either the methods and compositions as described in the present invention (see Examples 1-8) or to manufactures suggestions (Qiagen, Invitrogen, BioRad, or Promega). In particular, the quality of the plasmid DNA isolated using the lysis solution were compared to plasmid DNA isolated using QIAprep Miniprep kit, Wizard® Plus SV Minipreps DNA purification system (Promega), Aurum® Plasmid Mini Kit (BioRad), S.N.A.P. MiniPrep Kit (Invitrogen). Similar numbers of starting cells and elution volumes were used for each method. [0130]
  • Purified Plasmid DNA was compared via agarose gel analysis, spectrophotometric analysis, DNA sequencing and restriction enzyme digestion. [0131]
  • Agarose Gel Analysis: Approximately 4% of the plasmid DNA isolated using the QIAgen methods and the lysis methods described herein were loaded onto a 1% agarose gel containing ethidium bromide. Note that 1.5× Orange II dye was added to each sample prior to loading on the gel. In addition, 100 ng and 200 ng of pUC19 plasmid DNA was loaded as control DNA. As shown in FIG. 7A, plasmid DNA isolated according to the present methods provided comparable yields as QIAgen isolated plasmid DNA. [0132]
  • Spectrophotometric Analysis: Samples from each of the purification methods were analyzed using a SPECTRAmax Microplate Spectrophotometer (Molecular Devices Corp.) to determine DNA concentration and purity. Samples were diluted 20 fold in a UV-[0133] Star 96 well plate (Greiner bio-one Corp.). Absorbance readings were taken at the following wavelengths, 260, 280, and 212 nm. Each sample was run in duplicate. Concentration and A260/280 ratios were averaged to determine values presented in FIG. 7B. The data in FIG. 7B illustrates that the instant lysis method provides excellent concentrations and yields, comparable or better, to the QIAgen, Invitrogen, BioRad or Promega kits.
  • DNA Sequencing: Samples for each method were further analyzed by sequencing with ABI BigDye™ Terminator chemistry on the ABI 3700 sequencer. Sequencing was performed on the plasmid DNA and performed in duplicate. Template DNA was added to the reaction and varied according to vector and pelleted starting material. Between 200 ng and 300 ng of template DNA was aliquoted into a 96 well plate (Genemate-ISC Bioexpress) in a total volume of 41 μl. Sequencing parameters were as follows: step 1-94° C. for two minutes; step 2-94° C. for ten seconds; step 3-50° C. for five seconds; step 4-70° C. for four minutes; [0134] step 5—go to step two and repeat 25 times and step 6-10° C. hold.
  • Sequencing cleanup was performed prior to loading onto the ABI 3700 DNA sequencer. Approximately fifteen micro liters of 99% isopropanol was added to each well and heat sealed using Expender Heat Sealer and then vortexed briefly. Samples were incubated at room temperature for fifteen minutes and centrifuged at 1900×g for thirty minutes. Following centrifugation the heat seal was removed and the plate inverted on a paper towel and returned to the centrifuge plate carrier upside-down. The plate was spun at 500×g for one minute. The plate was removed and the centrifuge and DNA resuspended in ten micro liters of {fraction (1/10)}×TE and loaded onto the sequencer. Quality score was performed using PHRED based software version 0.020425.c (CodonCorporation). Passing results were determined to be those samples with 100 quality score ≧20. [0135]
  • As shown in Table 13, all five kits provided passing sequencing scores. Further, FIG. 8 provides an illustrative sequencing trace for each kit's DNA. The data indicates that the instant lysis and purification methods and compositions provide comparable quality DNA to the DNA isolated using the other kit manufacturers. Note that the instant method, including elution steps, is performed in approximately 14 minutes, whereas QIAgen takes approximately 28 minutes, Invitrogen takes approximately 31 minutes, Promega takes approximately 36 minutes, and BioRad Aurum kit takes approximately 23 minutes. This data illustrates the improved utility of the lysis solutions and methods described herein. [0136]
    TABLE 13
    Passing Sequencing Scores
    Passing Score
    pSV-β-galactosidase
    1.5 ml 3.0 ml
    Lysis
    6/6 100% 3/6 50%
    Compositions Of
    Present
    Invention
    Qiagen
    6/6 100% 5/6 83%
    Promega
    2/2 100%
    Invitrogen
    2/2 100%
    BioRad
    2/2 100%
  • Restriction Enzyme Digestion: Restriction digestion was performed on the pSV-β-gal vector using EcoRI, Hind III and Ned I. Restriction digestions were performed on 250 ng of plasmid DNA and 1 unit of each endonuclease. Buffer conditions are as described by the enzyme manufacturer. As shown in FIG. 9, the lysis isolated DNA provided comparable template DNA for restriction endonuclease as did other conventional isolation methods. [0137]
  • Example 10 PEG and Salt Binding Solution Drives NA Binding to Silica Fibers
  • The data in the following Example illustrates that a solution of PEG and salt can be used to force binding of low molecular weight nucleic acid to a glass fiber based NA capture matrix. Host cells having pUC19 were treated using the alkaline lysis method, as is well known in the art. Cleared lysate was placed on the silica based spin devices of the present invention and yield and A[0138] 260/280 readings on the isolated pUC19 determined. Alternatively, cleared lysate was combined with a 8.5% PEG/850 mM NaCl solution and treated substantially the same as the cleared lysate above.
  • As indicated in FIG. 10B, PEG and salt drive binding of the pUC19 in the cleared lysate to silica based fiber (lanes 1-4). In comparison, cleared lysate having no PEG and salt added failed to provide any detectable pUC19 binding to target silica based capture matrix (lanes 5-8). As shown in FIG. 10A, the best results are obtained when the lysis solution of the present invention is used in conjunction with the NA capture matrix of the present invention—where the lysis solution includes both PEG and salt at the pre-described concentrations (as shown in lanes 4-6 and 7-9). Note that lanes 1-3 show no purification of plasmid DNA when the lysis solution of the present invention contains no PEG or salt. [0139]
  • Example 11 Lysis Solution can be Added Directly to Cell Culture During Nucleic Acid Purification Methods of Present Invention
  • The data in the following Example illustrates that the lysis solution described herein is effective in the methods of the present invention even when added directly to a liquid bacterial culture (cells not pelleted). Lysis solution was prepared as described in Example 1. Samples were added to either a multi-layer glass fiber (5 μm and 3 μm) filter device or a single layer Whatman 23 μm glass fiber filter device. [0140]
  • Approximately 1.5 ml of pUC19/XL1blue transformed cell culture was mixed with 2.25 ml chilled lysis solution and cells vortexed for thirty seconds. Cells were allowed to incubate for 3 minutes at room temperature and approximately 930 μl of the lysate removed and added to either the multi-layer of single layer spin device for isolation of pUC19. Note that each culture was split into four samples, resulting in a yield that is ¼ of what would normally be expected from a [0141] 1.5 ml culture. Lysate was spun down in the spin devices and filters washed with approximately 500 μl wash buffer. Plasmid elution was performed as previously described. Absorbance readings and gel electrophoresis was performed as described above.
  • As shown in Table 14 and FIG. 11, the extraction of plasmid DNA directly from a liquid culture resulted in the extraction and purification of high quality DNA. Results showed little protein or RNA contamination (see A[0142] 260/280 readings and plasmid bands in FIG. 11). These results indicate that the methods and solutions of the present invention can be incorporated into a procedure that does not require the cells be pelleted before addition of the lysis solution. This is an impressive result—allowing the methods and solutions of the present invention to be used to further reduce the complexity and time required to isolate high quality nucleic acid from a target starting material.
    TABLE 14
    Data From Direct Mixing of Liquid Culture and Lysis
    Solution (All Readings Performed Twice)
    Filter Conc.
    Type Sample # A260 A280 A260/280 μg/ml A212
    Single 23 μm glass 1 0.03/0.03 0.02/0.02 1.72/1.75   33/32.7 2.5/2.4
    fiber filter
    2 0.03/0.04 0.02/0.02 1.77/1.7    33/34.9 2.6/2.6
    3 0.03/0.03 0.02/0.02 1.76/1.76 30.9/29.7 2.2/2.2
    4 0.04/0.04 0.02/0.02 1.73/1.79 37.8/37.6 3.5/3.5
    Multiple: 1 0.03/0.03 0.02/0.02 1.66/1.62 33.4/31.1 2.7/2.5
    5 and 3 μm glass
    fiber filter
    2 0.03/0.03 0.02/0.02 1.74/1.74 34.3/34.3 1.9/1.9
    3 0.04/0.04 0.02/0.02 1.64/1.55 37.6/37.3 1.8/1.9
    4 0.04/0.04 0.02/0.02 1.58/1.56 35.5/37.8 1.8/1.8
  • It will be clear that the invention is well adapted to attain the ends and advantages mentioned as well as those inherent therein. While a presently preferred embodiment has been described for purposes of this disclosure, various changes and modifications may be made which will readily suggest themselves to those skilled in the art and which are encompassed in the spirit of the invention disclosed herein and as defined in the appended claims. [0143]
  • All publications cited herein are hereby incorporated by reference. [0144]

Claims (50)

What is claimed is:
1. A lysis composition for lysing a host cell comprising:
a buffering agent; and
a zwitterionic detergent;
wherein at least a portion of protein in the host cell is solubilized by the zwitterionic detergent.
2. The composition of claim 1 further comprising lysozyme.
3. The composition of claim 2 further comprising RNase.
4. The composition of claim 2 further comprising DNase.
5. The composition of claim 2 further comprising polyethylene glycol.
6. The composition of claim 1 wherein said zwitterionic detergent is selected from the group consisting of n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and mixtures thereof.
7. The composition of claim 6 wherein said zwitterionic detergent is at a final concentration of from about 1% to about 5%.
8. The composition of claim 1 further comprising a chaotropic salt.
9. The composition of claim 1 wherein the composition has a final pH of from about 7.9 to about 8.4.
10. A kit for purifying low molecular weight nucleic acid from a host cell, the kit comprising:
a lysis solution for purifying low molecular weight nucleic acid from host cells, the lysis solution comprising a buffering agent and a zwitterionic detergent; and
a nucleic acid capture matrix for capturing low molecular weight nucleic acid.
11. The kit of claim 10 wherein said nucleic acid capture matrix comprises a spin column comprising a capture matrix material.
12. The kit of claim 11 wherein said capture matrix material comprises a glass fiber having an average pore size of at least 1 μm.
13. The kit of claim 11 wherein said capture matrix material comprises a glass fiber having an average pore size of at least 3 μm.
14. The kit of claim 13 further comprising a frit for support of the capture matrix material.
15. The kit of claim 10 further comprising:
a wash buffer for removal of contaminants from captured low molecular weight nucleic acid; and
an elution buffer for elution of captured low molecular weight nucleic acid from the nucleic acid capture matrix.
16. The kit of claim 10 wherein said zwitterionic detergent is selected from the group consisting of n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and mixtures thereof.
17. The kit of claim 16 wherein said zwitterionic detergent is at a final concentration of from about 0.2% to about 6%.
18. The kit of claim 10 further comprising lysozyme.
19. The kit of claim 10 further comprising RNase.
20. The kit of claim 10 further comprising DNase.
21. The kit of claim 10 further comprising a tube for culturing cells.
22. The kit of claim 21 wherein said tube for culturing cells is a lid-bac tube.
23. The kit of claim 10 wherein said nucleic acid capture matrix is integrated into at least one well of a ninety-six well plate, wherein the ninety-six well plate is included in the kit.
24. A method for purifying a low molecular weight nucleic acid from a host cell, the method comprising:
adding a lysing amount of lysis solution to host cells for the release of the low molecular weight nucleic acid from the host cells, said lysis solution comprising a zwitterionic detergent;
combining the host cells treated with the lysis solution with a nucleic acid capture matrix, the nucleic acid capture matrix having at least one layer of capture matrix material having an average pore size of at least 1 μm for the capture of the low molecular weight nucleic acid; and
eluting the low molecular weight nucleic acid from the nucleic acid capture matrix.
25. The method of claim 24 wherein said zwitterionic detergent in said lysis solution is at from about 0.2% to about 6%.
26. The method of claim 25 wherein said zwitterionic detergent in said lysis solution is at from about 1% to about 5%.
27. The method of claim 24 wherein said zwitterionic detergent in said lysis solution is selected from the group consisting of n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and mixtures thereof.
28. The method of claim 24 wherein said lysis solution is chilled to a temperature below room temperature before addition to the host cells.
29. The method of claim 28 further comprising:
incubating the lysis solution on the host cells at room temperature for at least three minutes prior to combining with the nucleic acid capture matrix.
30. The method of claim 29 wherein the incubation is for at least five minutes.
31. The method of claim 24 further comprising:
washing the nucleic acid capture matrix having the captured low molecular weight nucleic acid with a wash buffer prior to eluting.
32. The method of claim 24 wherein said lysis solution further comprises polyethylene glycol.
33. The method of claim 32 wherein said polyethylene glycol is at a final concentration of from about 2% to about 20%.
34. The method of claim 24 wherein said lysis solution further comprises lysozyme.
35. The method of claim 24 wherein said lysis solution further comprises RNase.
36. The method of claim 24 wherein said lysis solution further comprises DNase.
37. The method of claim 24 wherein said lysis solution further comprises a chaotropic salt.
38. The method of claim 24 wherein said low molecular weight nucleic acid comprises a plasmid DNA.
39. A composition for releasing extrachromosomal DNA from a host cell comprising a solution having from about 0.2% to about 6% of a zwitterionic detergent.
40. The composition of claim 39 wherein said zwitterionic detergent is selected from the group consisting of n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and mixtures thereof.
41. The composition of claim 40 further comprising lysozyme.
42. The composition of claim 41 further comprising RNase.
43. The composition of claim 41 further comprising polyethylene glycol.
44. The composition of claim 41 further comprising chaotropic salt.
45. A composition for solubilizing cellular protein during the separation of cellular protein from nucleic acid comprising a detergent is selected from the group consisting of n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, n-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and mixtures thereof.
46. The composition of claim 45 wherein said detergent is at a final concentration of from about 0.2% to about 6%.
47. The composition of claim 46 wherein said detergent is at a final concentration of from about 1% to about 5%.
48. A lysis composition for isolating nucleic acid from a cleared lysate comprising:
a buffering agent;
polyethylene glycol; and
a salt;
wherein the lysis composition is added to the cleared lysate, and the combination of cleared lysate and lysis composition is added to a silica fiber for capture of the nucleic acid on the silica fiber.
49. A method for purifying a low molecular weight nucleic acid from a host cell in a cell culture, the method comprising:
adding a lysing amount of lysis solution to the cell culture for release of the low molecular weight nucleic acid from the host cell;
combining the host cells treated with the lysis solution with a nucleic acid capture matrix, the nucleic acid capture matrix having at least one layer of capture matrix material having an average pore size of at least 1 μm for the capture of the low molecular weight nucleic acid; and
eluting the low molecular weight nucleic acid from the nucleic acid capture matrix.
50. The method of claim 49 wherein the lysis solution is added to the cell culture at a ratio of lysis solution to volume of cell culture of about 1:2 to about 3:1.
US10/387,646 2003-03-12 2003-03-12 Methods and compositions for purification of nucleic acid from a host cell Abandoned US20040180445A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/387,646 US20040180445A1 (en) 2003-03-12 2003-03-12 Methods and compositions for purification of nucleic acid from a host cell
AU2003297244A AU2003297244A1 (en) 2003-03-12 2003-12-16 Methods and compositions for purification of nucleic acid from a host cell
EP03816282A EP1601966B1 (en) 2003-03-12 2003-12-16 Methods and compositions for purification of nucleic acid from a host cell
DE60327471T DE60327471D1 (en) 2003-03-12 2003-12-16 METHOD AND COMPOSITIONS FOR CLEANING NUCLEIC ACID FROM A HOST CELL
PCT/US2003/040175 WO2004081175A2 (en) 2003-03-12 2003-12-16 Methods and compositions for purification of nucleic acid from a host cell
CNA2003801101423A CN1768265A (en) 2003-03-12 2003-12-16 Methods and compositions for purification of nucleic acid from a host cell
AT03816282T ATE430195T1 (en) 2003-03-12 2003-12-16 METHOD AND COMPOSITIONS FOR PURIFYING NUCLEIC ACID FROM A HOST CELL
US12/358,128 US7863050B2 (en) 2003-03-12 2009-01-22 Methods and compositions for purification of nucleic acid from a host cell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/387,646 US20040180445A1 (en) 2003-03-12 2003-03-12 Methods and compositions for purification of nucleic acid from a host cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/358,128 Division US7863050B2 (en) 2003-03-12 2009-01-22 Methods and compositions for purification of nucleic acid from a host cell

Publications (1)

Publication Number Publication Date
US20040180445A1 true US20040180445A1 (en) 2004-09-16

Family

ID=32961928

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/387,646 Abandoned US20040180445A1 (en) 2003-03-12 2003-03-12 Methods and compositions for purification of nucleic acid from a host cell
US12/358,128 Expired - Lifetime US7863050B2 (en) 2003-03-12 2009-01-22 Methods and compositions for purification of nucleic acid from a host cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/358,128 Expired - Lifetime US7863050B2 (en) 2003-03-12 2009-01-22 Methods and compositions for purification of nucleic acid from a host cell

Country Status (7)

Country Link
US (2) US20040180445A1 (en)
EP (1) EP1601966B1 (en)
CN (1) CN1768265A (en)
AT (1) ATE430195T1 (en)
AU (1) AU2003297244A1 (en)
DE (1) DE60327471D1 (en)
WO (1) WO2004081175A2 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259162A1 (en) * 2003-05-02 2004-12-23 Sigma-Aldrich Co. Solid phase cell lysis and capture platform
US20050009036A1 (en) * 2003-07-11 2005-01-13 Applera Corporation Methods and kits for obtaining nucleic acid from biological samples
US20050244847A1 (en) * 2003-11-26 2005-11-03 Eppendorf Ag Methods and compositions for in vitro amplification of extrachromosomal nucleic acid
US20060046261A1 (en) * 2004-08-25 2006-03-02 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
KR100622606B1 (en) 2005-06-16 2006-09-11 (주)엘피스바이오텍 Composition for the purification of plasmid dna by one step and rapid purification method thereof
US20060240448A1 (en) * 1999-05-14 2006-10-26 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
US20060281142A1 (en) * 2005-04-19 2006-12-14 E.I. Du Pont De Nemours And Company Combined sample enrichment and disruption
US20070172855A1 (en) * 2005-12-09 2007-07-26 Promega Corporation Nucleic acid purification with a binding matrix
EP1846579A2 (en) * 2005-01-21 2007-10-24 The New York Blood Center, Inc. Method for extraction and identification of nucleic acids
US20070249821A1 (en) * 2006-03-08 2007-10-25 Promega Corporation Small RNA purification
US20080003574A1 (en) * 2006-06-28 2008-01-03 Sigma-Aldrich Co. Kits for RNA extraction
US20080146789A1 (en) * 2007-03-20 2008-06-19 Braman Jeffrey C Methods for the separation of biological molecules using dioxolane
EP1983051A2 (en) 2007-04-20 2008-10-22 Roche Diagnostics GmbH Isolation and purification of nucleic acid molecules with solid phase
WO2009129524A2 (en) * 2008-04-18 2009-10-22 The General Hospital Corporation High-throughput plasmid dna preparation
US8039613B2 (en) 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US8062843B2 (en) * 2006-12-13 2011-11-22 Roche Diagnostics Operations, Inc. Use of acetals for isolation of nucleic acids
US8222397B2 (en) 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
US10072284B2 (en) 2012-06-21 2018-09-11 Monsanto Technology Llc Lysis buffer and methods for extraction of DNA from plant material
CN113186185A (en) * 2020-01-14 2021-07-30 东北林业大学 Method for efficiently enriching host DNA from mammal excrement

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007006799A (en) * 2005-06-30 2007-01-18 Tokyo Institute Of Technology Method and kit for purifying plasmid dna
CA2659632A1 (en) * 2006-08-01 2008-02-07 Applera Corporation Detection of analytes and nucleic acids
WO2012013733A1 (en) * 2010-07-29 2012-02-02 F. Hoffmann - La Roche Ag Generic sample preparation
US9725754B2 (en) * 2010-07-29 2017-08-08 Sean F. Boyle Generic sample preparation
BR112013004401A2 (en) * 2010-08-30 2016-05-17 Hoffmann La Roche method for producing a lipid particle, the lipid particles themselves and their use.
US8791063B2 (en) 2011-08-25 2014-07-29 Hoffmann-La Roche, Inc. Shortened tetranectin-apolipoprotein A-I fusion protein, a lipid particle containing it, and uses thereof
ES2567091T3 (en) * 2012-04-05 2016-04-19 F. Hoffmann-La Roche Ag Amine compounds for the selective preparation of biological samples
CN107254466A (en) * 2017-07-01 2017-10-17 济凡生物科技(北京)有限公司 A kind of one-step method extracts the kit and method of DNA
WO2024006548A1 (en) * 2022-07-01 2024-01-04 Sherlock Biosciences, Inc. Nucleic acid preparation

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652517A (en) * 1984-06-11 1987-03-24 Diagnostic Research Limited Partnership Methods for the in vitro detection and identification of unknown pathogens or genetic entities
US4681847A (en) * 1981-04-30 1987-07-21 Kyowa Hakko Kogyo Co., Ltd. Novel lysozyme-sensitive microorganism
US4992531A (en) * 1987-06-15 1991-02-12 Bunge (Australia) Pty. Ltd. Production of proteins in active forms
US5128247A (en) * 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5783686A (en) * 1995-09-15 1998-07-21 Beckman Instruments, Inc. Method for purifying nucleic acids from heterogenous mixtures
US20020012982A1 (en) * 2000-07-13 2002-01-31 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
US6545144B2 (en) * 2001-02-10 2003-04-08 Eppendorf Ag Method for isolating nucleic acids from a liquid sample containing nucleic acids
US6548256B2 (en) * 2000-07-14 2003-04-15 Eppendorf 5 Prime, Inc. DNA isolation method and kit
US20030073830A1 (en) * 2001-10-12 2003-04-17 Heath Ellen M. Compositions and methods for using a solid support to purify RNA
US20030134412A1 (en) * 2001-03-21 2003-07-17 Thomas Kolzau Method for isolating plasmids from suspended bacterial or yeast cells
US20030166916A1 (en) * 2000-02-11 2003-09-04 Thomas Kolzau Method for purifying nucleic acids
US20030191302A1 (en) * 2000-02-11 2003-10-09 Thomas Kolzau Use of functionalised porous membranes or matrices for purification of nucleic acids and corresponding methods
US20040157219A1 (en) * 2003-02-06 2004-08-12 Jianrong Lou Chemical treatment of biological samples for nucleic acid extraction and kits therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295859B1 (en) * 1987-06-15 1994-11-17 Southern Cross Biotech Pty.Ltd. Production of proteins in active forms
GB9020594D0 (en) * 1990-09-21 1990-10-31 Procter & Gamble Cleansing compositions
EP0733099B1 (en) * 1994-01-07 1998-05-27 QIAGEN GmbH Process for reducing high-molecular structures
GB9425138D0 (en) * 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
GB2297975B (en) * 1995-01-14 1998-08-05 Procter & Gamble Cleansing compositions
GB9607963D0 (en) * 1996-04-17 1996-06-19 Unilever Plc Cleansing composition
EP1950312A1 (en) * 1998-02-02 2008-07-30 QIAGEN North American Holdings, Inc. Processes for isolating, amplifying and characterizing DNA
EP1137431A1 (en) * 1998-12-04 2001-10-04 Provalis UK Limited Pharmaceutical compositions containing insulin
ES2305023T3 (en) * 2000-10-31 2008-11-01 F. Hoffmann-La Roche Ag METHODS FOR THE ANALYSIS OF NON-PROTEIN COMPONENTS USING A PROTEASE OF A BACILO CEPA.
US6534472B1 (en) * 2001-11-13 2003-03-18 Colgate-Palmolive Company Antibacterial cleaning wipe
EP1585480A4 (en) * 2003-01-21 2008-12-03 Smithkline Beecham Corp Erbb4 co-crystal

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681847A (en) * 1981-04-30 1987-07-21 Kyowa Hakko Kogyo Co., Ltd. Novel lysozyme-sensitive microorganism
US4652517A (en) * 1984-06-11 1987-03-24 Diagnostic Research Limited Partnership Methods for the in vitro detection and identification of unknown pathogens or genetic entities
US4992531A (en) * 1987-06-15 1991-02-12 Bunge (Australia) Pty. Ltd. Production of proteins in active forms
US5128247A (en) * 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5783686A (en) * 1995-09-15 1998-07-21 Beckman Instruments, Inc. Method for purifying nucleic acids from heterogenous mixtures
US20030166916A1 (en) * 2000-02-11 2003-09-04 Thomas Kolzau Method for purifying nucleic acids
US20030191302A1 (en) * 2000-02-11 2003-10-09 Thomas Kolzau Use of functionalised porous membranes or matrices for purification of nucleic acids and corresponding methods
US20020012982A1 (en) * 2000-07-13 2002-01-31 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
US6548256B2 (en) * 2000-07-14 2003-04-15 Eppendorf 5 Prime, Inc. DNA isolation method and kit
US6545144B2 (en) * 2001-02-10 2003-04-08 Eppendorf Ag Method for isolating nucleic acids from a liquid sample containing nucleic acids
US20030134412A1 (en) * 2001-03-21 2003-07-17 Thomas Kolzau Method for isolating plasmids from suspended bacterial or yeast cells
US20030073830A1 (en) * 2001-10-12 2003-04-17 Heath Ellen M. Compositions and methods for using a solid support to purify RNA
US20040157219A1 (en) * 2003-02-06 2004-08-12 Jianrong Lou Chemical treatment of biological samples for nucleic acid extraction and kits therefor

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240448A1 (en) * 1999-05-14 2006-10-26 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
US20040259162A1 (en) * 2003-05-02 2004-12-23 Sigma-Aldrich Co. Solid phase cell lysis and capture platform
US20050009036A1 (en) * 2003-07-11 2005-01-13 Applera Corporation Methods and kits for obtaining nucleic acid from biological samples
US20050244847A1 (en) * 2003-11-26 2005-11-03 Eppendorf Ag Methods and compositions for in vitro amplification of extrachromosomal nucleic acid
US20080064093A1 (en) * 2004-08-25 2008-03-13 Sigma Aldrich Company Compositions and methods employing zwitterionic detergent combinations
US20060046261A1 (en) * 2004-08-25 2006-03-02 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US7282475B2 (en) * 2004-08-25 2007-10-16 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US7897376B2 (en) * 2004-08-25 2011-03-01 Sigma-Aldrich Co. Method for extracting a target product from a host cell employing zwitterionic detergent combinations
EP1846579A2 (en) * 2005-01-21 2007-10-24 The New York Blood Center, Inc. Method for extraction and identification of nucleic acids
EP1846579A4 (en) * 2005-01-21 2008-12-24 New York Blood Ct Inc Method for extraction and identification of nucleic acids
US20060281142A1 (en) * 2005-04-19 2006-12-14 E.I. Du Pont De Nemours And Company Combined sample enrichment and disruption
KR100622606B1 (en) 2005-06-16 2006-09-11 (주)엘피스바이오텍 Composition for the purification of plasmid dna by one step and rapid purification method thereof
US8030034B2 (en) 2005-12-09 2011-10-04 Promega Corporation Nucleic acid purification with a binding matrix
US20070172855A1 (en) * 2005-12-09 2007-07-26 Promega Corporation Nucleic acid purification with a binding matrix
US8658360B2 (en) 2005-12-09 2014-02-25 Promega Corporation Nucleic acid purification with a binding matrix
US20120309952A1 (en) * 2006-03-08 2012-12-06 Promega Corporation Small rna purification
US20070249821A1 (en) * 2006-03-08 2007-10-25 Promega Corporation Small RNA purification
US20080003574A1 (en) * 2006-06-28 2008-01-03 Sigma-Aldrich Co. Kits for RNA extraction
US20080003575A1 (en) * 2006-06-28 2008-01-03 Sigma-Aldrich Co. Methods and composition for RNA extraction
US8062843B2 (en) * 2006-12-13 2011-11-22 Roche Diagnostics Operations, Inc. Use of acetals for isolation of nucleic acids
US20080146789A1 (en) * 2007-03-20 2008-06-19 Braman Jeffrey C Methods for the separation of biological molecules using dioxolane
US20080319182A1 (en) * 2007-04-20 2008-12-25 Christian Birkner Isolation and purification of nucleic acids with a solid phase
US8101744B2 (en) 2007-04-20 2012-01-24 Roche Diagnostics Operations, Inc. Isolation and purification of nucleic acids with a solid phase
EP1983051A2 (en) 2007-04-20 2008-10-22 Roche Diagnostics GmbH Isolation and purification of nucleic acid molecules with solid phase
WO2009129524A3 (en) * 2008-04-18 2009-12-17 The General Hospital Corporation High-throughput plasmid dna preparation
WO2009129524A2 (en) * 2008-04-18 2009-10-22 The General Hospital Corporation High-throughput plasmid dna preparation
US8039613B2 (en) 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US8222397B2 (en) 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
US8519119B2 (en) 2009-08-28 2013-08-27 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US10072284B2 (en) 2012-06-21 2018-09-11 Monsanto Technology Llc Lysis buffer and methods for extraction of DNA from plant material
CN113186185A (en) * 2020-01-14 2021-07-30 东北林业大学 Method for efficiently enriching host DNA from mammal excrement

Also Published As

Publication number Publication date
EP1601966B1 (en) 2009-04-29
AU2003297244A1 (en) 2004-09-30
WO2004081175A3 (en) 2005-02-03
EP1601966A2 (en) 2005-12-07
WO2004081175A2 (en) 2004-09-23
AU2003297244A8 (en) 2004-09-30
CN1768265A (en) 2006-05-03
DE60327471D1 (en) 2009-06-10
EP1601966A4 (en) 2007-05-02
US7863050B2 (en) 2011-01-04
US20090246859A1 (en) 2009-10-01
ATE430195T1 (en) 2009-05-15

Similar Documents

Publication Publication Date Title
US7863050B2 (en) Methods and compositions for purification of nucleic acid from a host cell
US10947527B2 (en) Compositions and methods for purifying nucleic acids from stabilization reagents
JP4804347B2 (en) Compositions and methods for purifying RNA using a solid support
US6548256B2 (en) DNA isolation method and kit
JP4369619B2 (en) Rapid and simple isolation method for circular nucleic acids
EP1773996B1 (en) Compositions and methods for using a solid support to purify dna
US6177278B1 (en) Nucleic acid purification and process
JP3787354B2 (en) Nucleic acid isolation method
US8852929B2 (en) Plasmid DNA isolation
JPH08501321A (en) Method for purifying and separating nucleic acid mixture by chromatography
JP4435787B2 (en) Formulations and methods for denaturing proteins
EP3783113B1 (en) Isolation of high molecular weight dna using beads
AU2003204489B2 (en) Process of extracting nucleic acid and process of simultaneously carrying out extraction and purification of nucleic acid
US20140206009A1 (en) Microfluidic device-based nucleic acid purification method
US20030228600A1 (en) DNA isolation method and kit
JP2001083050A (en) Nucleic acid recovering method and reagent kit

Legal Events

Date Code Title Description
AS Assignment

Owner name: EPPENDORF 5 PRIME, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOMANICO, MICHAEL J.;MEYERS, MATT;KEANE, KRISTIAN;AND OTHERS;REEL/FRAME:013788/0691;SIGNING DATES FROM 20030404 TO 20030506

AS Assignment

Owner name: EPPENDORF AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EPPENDORF 5 PRIME, INC.;REEL/FRAME:016182/0185

Effective date: 20050303

AS Assignment

Owner name: QIAGEN NORTH AMERICAN HOLDINGS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EPPENDORF AG;REEL/FRAME:018923/0314

Effective date: 20061218

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION